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ABSTRACT 
Mitochondria are important in producing energy for metabolic processes through 
oxidative phosphorylation (OXPHOS) and release factors to regulate programmed 
cell death called apoptosis. Mitochondria have its own set of DNA called 
mitochondrial DNA (mtDNA), including 13 protein coding genes, 2 rRNAs, 22 
tRNAs and a non-coding displacement-loop (D-loop) region. 
MtDNA has a higher mutation rate than nuclear DNA. This is because of: (1) the 
production of reactive oxygen species (ROS) during OXPHOS and damages mtDNA; 
(2) the absence of histories to protect mtDNA; and (3) the base-excision repair being 
the remaining repair system and the poor fidelity of DNA polymerase y. 
In the past several years, high frequency of somatic mtDNA mutations had been 
reported in various cancers. In this study, the frequency and distribution of somatic 
mtDNA mutations in HBV-associated hepatocellular carcinoma in the Chinese 
population was investigated. The entire mitochondrial genome in ten HCC patients 
and their corresponding non-tumor liver tissues were analyzed by automated 
sequencing. 
One hundred and seventy-six sequence variants were found in the 10 HCC and their 
corresponding non-tumor specimens. One hundred and twenty-two were previously 
reported polymorphisms, whilst 44 were novel polymorphisms. Twelve somatic 
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mutations were found in 70% (7 of 10) of HCC cases. The mutation sites were 
distributed unevenly, with five (42%) located in the polymorphic non-coding D-loop 
region. Altered protein sequences were found in three of the four mutations of the 
ND5 gene. The wild-type protein sequences were conserved with other organisms, 
which may alter the protein structure and function when mutation occurred. 
Matched blood samples from HCC patients were included in this study. Somatic 
mutations were not present in the paired lymphocytes of the corresponding patients, 
indicating that these sequence changes may be related to the physiological changes in 
tumors. Tumor-specific mtDNA mutations cannot be detected in matched serum 
samples using automated sequencing. More sensitive method can be used to detect 
these mutations as a non-invasive method to monitor patients with HCC. 
Investigations were also done on a mononucleotide repeat between 303-315 bp 
(D310) and a dinucleotide CA repeat between 514-525 bp in 50 HCC specimens, the 
frequencies of mutations at these two sites were 26% and 2% respectively. Although 
most of the mutations at D310 were normal polymorphisms (6 to 9Cs in the first 
stretch), 2 deletions with more than 5-bp were found. The deletion of D310 at the 
conserved sequence block II region may affect mtDNA replication and gene 
expression. 
From the sequencing results, somatic mutations at the coding genes with changed 
amino acid sequence, the polymorphic D-loop, and alterations at D310 could be a 
potential diagnostic marker for HCC. 
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By Kaplan-Meier method, a significant correlation between somatic mutations in 
D310 and both overall survival and disease-free survival was found. According to 
Cox regression analysis, this alteration was found to be an independent genetic 
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突變與病人的生存時間呈顯著的負相關，即突變病人的生存時間較短，這類突 
變可能成爲預後判斷的指標。 
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Section 1. Introduction of Hepatocellular 
Carcinoma 
1.1 Epidemiology of Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is one of the commonest malignant tumors in the 
world. It represents four percent of the malignancies worldwide, with an incidence of 
1,000,000 new cases a year. The incidence rate is relatively low in western 
developed countries (one to four per 100,000 population), while the incidence is 
relatively higher in China, Taiwan, Korea, and sub-Saharan Africa (20 to 150 cases 
per 100,000 inhabitants) (Dominguez-Malagon et al, 2001). The incidence rate is 
increasing in the past decades. 
The age of onset in HCC is variable in different parts of the world. The occurrence of 
HCC in South Africa is between 35 and 45 years, while in China and Japan is 
between 45 and 55 years, and in United States and Western Europe is after 55 years 
(Dominguez-Malagon et al., 2001). In general, the occurrence of HCC increases 
progressively with age. HCC is more common in males than in females, ranging 
from eight to one in high incidence areas to four to one in low incidence areas. 
Hong Kong is an area with a high incidence of HCC, about 1,700 new cases are 
reported annually and it is the second largest leading cause of death in cancer. There 
were 1,420 deaths in 1999, contribute to about 12.9% of total cancer death 
(Department of Health, 1999-2000). The importance of this disease is not only 
because of its high incidence, but also of its poor prognosis (Parkin et al., 1984). 
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There is a high possibility of postoperative recurrence, which is a major obstacle for 
improving the survival and prognosis in HCC patients (Qin et aL, 2002). 
1.2 Etiologies of HCC 
The heterogeneous geographical distribution of HCC gives clues to the identification 
of major risk factors, including chronic infection with hepatitis B virus (HBV) and 
hepatitis C vims (HCV), dietary intake of hepatocarcinogen aflatoxin pi , 
hemochromatosis, alcohol, industrial agents and deficiency in al-antitripsin 
(Dominguez-Malagon et aL, 2001). Those factors that occur frequently in Chinese 
population will be discussed below. 
1.2.1 Hepatitis B Virus and Hepatitis C Virus 
HBV is a DNA virus belonging to the family of Hepadnaviridae. The main pathways 
of transmittions include: (1) infection through blood, (2) infection through body 
fluids such as semen and vaginal secretion, and (3) vertical transmittion from 
mother-to-infant. The estimated number of chronic HBV carriers world-wide reaches 
400 million. In Hong Kong, about 10% of the population are infected with HBV, i.e. 
carrier of surface antigen of the HBV. 
HBV has a significant role in the development of HCC because more than 80 percent 
of HCC patients had chronic HBV infection (Liew et aL, 1999). The risk for a 
chronic HBV carrier having HCC is 100 times higher than an uninfected individual 
(Beasley et aL, 1981). 
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Chronic infection of HBV in liver may result in liver injury with inflammation, 
regeneration, fibrosis and possibly cirrhosis which predisposes to HCC. Since not all 
HBV-related HCC occurs in the presence of liver cirrhosis, it implies that HBV may 
have some intrinsic hepatocarcinogenic properties. One of the properties of HBV is 
its integration into the host nuclear genome. The expression of hepatitis B virus X 
protein (HBx protein) from HBV may promote the growth and development of liver 
cancer through survival and growth of transformed hepatocytes (Seow et al, 2001). 
HCV was discovered in 1989 by Kuo et al. (Kuo et al., 1989). It was infected 
predominantly through skin lesion and infected blood products when HCV has not 
been identified. Unlike HBV, HCV is a positive strand RNA vims in which there is 
no reverse transcription and integration of the viral genome into the host cells (Choo 
et al., 1990). Dominguez-Malagon et al suggested that there is a stronger association 
of HCV infection and the development of HCC than with HBV infection 
(Dominguez-Malagon et al, 2001). 
1.2.2 Aflatoxins and Alcohol 
Aflatoxins are toxins produced from fungi Aspergillus flavus and Aspergillus 
parasiticus. Improper storage of grain crops such as com, peanut and rice would lead 
to fungi growth and aflatoxin release, which contaminates the crops (Wild et al., 
2000). After ingestion of contaminated crops into the body, liver is responsible to 
metabolize the aflatoxins. Metabolites of this toxin promote apurinic sites targeting 
to form adducts with DNA, and induce a guanine to thymine point mutation in the 
third base of codon 249 of the tumor suppressor gene p53. The defect in p53 may 
promote cancer progression (Ozturk, 1991). 
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An association was found between codon 249 mutation in p53 and HBV infection, 
and this synergistic effect may promote higher rates of HCC development. In Qidong 
Province of China and sub-Saharan Africa where aflatoxin p 1 contamination in food 
are present, high incidence of p53 mutation at codon 249 was reported. However, 
this mutation also occurs at a lower incidence rate in regions showing low to 
moderate exposure of aflatoxin with high occurrence of HCC (Beijing, Taiwan, 
Hong-Kong, Thailand) (Buendia, 2000). Moreover, this mutational event at codon 
249 is not entirely specific for aflatoxin exposure and may occur occasionally in 
tumors from other regions of the world (Kar et al, 1993; Dominguez-Malagon et al., 
2001). Therefore, the actual role of aflatoxin in HCC needs further investigation. 
Alcohol, a hepatotoxic agent which can induce liver cirrhosis, is a major risk factor 
for HCC particularly in areas where HBV infection is uncommon, like in the 
Western countries. Alcohol is a co-carcinogen as it has not been demonstrated to 
have a carcinogenic effect on experimental animals. The combination of heavy 
alcohol use and chronic infection of HCV increases the risk of HCC (Dominguez-
Malagon et a/., 2001). 
Major Diagnostic and Prognostic Markers of HCC 
Diagnostic markers are factors which can detect the presence of new tumor or relapse 
of the tumor in a preclinical stage. Application of these markers may identify the 
disease at an early stage. Prognostic markers are factors which can assess the 
biological aggressiveness of the tumor after surgical resection. These markers can 
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provide information for physicians to apply suitable therapies on patients (Chiesa et 
al, 1999). 
1.3.1 Biochemical Tumor Markers 
Alpha-fetoprotein (AFP) is a protein normally produced by the liver and yolk sac of 
a fetus. The AFP level decreases soon after birth and probably has no normal 
function in adults. However, high level of AFP is present in patients with several 
liver disorders and HCC. Patients with high AFP levels at diagnosis tend to have 
larger tumor size and shorter median survival rates than patients with normal AFP. 
Messenger RNA (mRNA) of AFP can be detected in peripheral blood to predict post-
surgical recurrence or metastasis (Ijichi et al., 2002; Qin et al., 2002). AFP level in 
serum is thus a useful marker not only for diagnosis, but also a good prognostic 
indicator for HCC patients (Tangkijvanich et al., 2000). 
A number of biomolecules are produced in hepatocytes: albumin, bilirubin, and 
enzymes like alkaline phosphatase, alanine transaminase, aspartate aminotransferase 
and lactate dehydrogenase for various metabolic functions in liver. When 
hepatocytes are injured or damaged due to HCC or other liver disorders, they will 
release into the blood stream. The serum levels of these substances are the 
components in liver function tests. They are common diagnostic markers to monitor 
liver diseases and are also suggested to be prognostic factors in various studies 
(Aoyagi et al., 1998; Use et cd.，1998; Qin et al., 2002). 
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1.3.2 Clinico-pathological Features of HCC 
At present, a number of clinical and pathological features of tumor, including tumor 
size, number of nodules, grading, capsule state, cell differentiation, resection margin, 
venous invasion, inflammatory cell infiltration are implied as factors for recurrence 
and prognosis of patients with HCC (Lise et aL, 1998; Qin et al., 2002). 
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Section 2. The Mitochondrion 
The word 'mitochondria' ('mitochondrion' in singular) comes from Greek. Around 
the year 1850, microscopists used the word 'grains' (chondria in Greek) to describe 
the morphology of distinct cell structures. Later, improvements in staining yielded 
more accurate morphological descriptions, the same tissues were seen as 'threads' 
(mito in Greek) (Scheffler，1999). 
The mitochondrion is an energy-generating organelle located in the cytoplasm of the 
cell. This 'power house of the cell' is thought to have arisen about 1.5 to 2 billion 
years ago from a symbiotic association between an oxidative prokaryotic bacterium 
and a more complex glycolytic proto-eukaryotic cell. The result was a proto-
eukaryotic cell, the new endosymbiotic bacteria was called mitochondria (Green et 
al., 1998; Wallace et al.’ 1998; Wallace, 1999). 
The size of mitochondria is variable, but in hepatocytes and fibroblasts, they have a 
sausage-like shape with dimensions of 3-4 i^m in length and approximately 1 \im in 
diameter. The mitochondria have a double membrane with the unwrinkled outer 
membrane completely surrounds the organelle. The inner membrane has inward 
foldings called cristae, providing a large surface area for mitochondrial functions. 
The inner component of mitochondria is called matrix which is a concentrated 
aqueous solution containing proteins and lipids involved in metabolism (Wallace et 
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al., 1998; Wallace, 1999). DNA in mitochondria, called mitochondrial DNA 
(mtDNA), is able to replicate and express mtDNA genes. 
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2.1 Structure of the Mitochondrial Genome 
The first confirmed identification of mtDNA was reported by Nass and Nass in 1963 
(Nass et al, 1963), while the complete sequence of human mtDNA was published in 
1981 (Anderson et al.’ 1981). It is much earlier than the accomplishment of nuclear 
human genome. 
The mtDNA is a supercoiled, double-stranded circular molecule, with a heavy strand 
(H-strand) and a light strand (L-strand). Most of the genes are encoded by H-strand, 
except one protein and eight transfer RNAs (tRNA) are encoded by L-strand. The 
human mitochondrial genome consists of 16,569 base pairs and is one of the smallest 
mitochondrial genomes found in eukaryotes. The small genome can increase its 
replication rate, and ensure transmission to the two daughter cells at cytokinesis 
(Wallace, 1999). 
Depending on the cell type, there are 1 to 10 mitochondria per cell, and each 
mitochondrion has about 100 copies of mtDNA. In total, there would be about 100 to 
1,000 copies of mtDNA per cell (Wallace, 1999). There are hundreds of thousands of 
mtDNAs in female egg, while male sperm has only a few (Wallace et al., 1998). 
Therefore, it is believed that nearly all mtDNA molecules are from the female after 
fusion of gametes. This proved that mtDNA is exclusively maternally inherited. 
There are a total of 37 genes in the mtDNA, coding for 13 polypeptides of the 
mitochondrial electron respiratory chain, 22 tRNAs and 2 rRNAs for the synthesis of 
polypeptides (Larsson et al., 1999; Penta et al., 2001). Other proteins required for 
energy producing processes are encoded by the nuclear genome. More than 90% of 
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the mitochondrial genome is encoded with genes called the coding sequence, while 
the proportion of intron sequence (called non-coding sequence) is relatively small 
compare with that of nuclear genome. The mtDNA is transcribed in the form ofpoly-
cistronic mRNA. Detailed descriptions of the components of mitochondrial genome 
are illustrated in Sections 2.1.1 to 2.1.7 and Table 2.1. The mitochondrial genome 
map is shown in Figure 2.1. 
2.1.1 Nicotinamide Adenine Dinucleotide Dehydrogenase 
The mitochondrial-encoded nicotinamide adenine dinucleotide dehydrogenase (ND) 
is also called NADH: ubiquinone oxidoreductase. Seven proteins are encoded by the 
mitochondrial genome: subunits 1，2，3，4，4L, 5 and 6. They represent seven of 43 
polypeptides of complex I in a respiratory process called oxidative phosphorylation 
(OXPHOS). The molecular size of subunit 4L is the smallest (296 bp, 11 kDa of 
ND4L protein), while that of subunit 5 is the largest (1812 bp, 67 kDa of ND5 
protein). The complex receives electrons borne on NAD+ from various pathways in 
OXPHOS. 
2.1.2 Cytochrome b 
The cytochrome b-ci complex (also called ubiquinol: cytochrome c oxidoreductase) 
is present at the inner membrane of mitochondria. The cytochrome b gene {CYB) 
encodes one of eleven subunits for this Complex III. It is a 43 kDa protein with 
molecular size of 1141 bp. It contains an iron-sulfur and three heme groups to 
receive electrons from coenzyme Q (CoQ) in electron transport chain. 
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2.1.3 Cytochrome c Oxidase 
Three cytochrome c oxidase genes {COI, COII and COIII) are encoded by the 
mitochondrial genome as constituents of Complex IV. Their molecular sizes are 
1542 bp for COI (57 kDa protein), 684 bp for COII (25.5 kDa protein) and 784 bp 
for COIII (30 kDa protein). They have the role in receiving electrons from 
cytochrome c and combine with molecular oxygen to form water. 
2.1.4 ATP Synthase 
ATP synthase is also called FqFi synthase complex. It is located within the 
mitochondrial membrane and contains a transmembrane channel which extends into 
the mitochondrial matrix. It can bind ATP, ADP, and Pj to catalyze ATP synthesis. 
MtDNA encodes two genes: ATP6 and ATP8 in a total of 14 subunits of respiratory 
Complex V. They have the molecular sizes of 681 bp (25 kDa) and 207 bp (8 kDa) 
respectively. 
2.1.5 Ribosomal RNA 
There are two ribosomal RNA (rRNA) encoded in mtDNA: the small subunit 12S 
(954 bp) and the large subunit 16S (1559 bp). The two ribosomal RNAs combine 
with an array of different proteins to form ribosomes, which provide the site used for 
protein synthesis called translation. During translation, the ribosomes recognize and 
convert the codon of mRNA for binding the respective tRNA with amino acid 
(aminoacyl-tRNA) to produce proteins (Griffiths et g/.�2000). 
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2.1.6 Transfer RNA 
There are totally 22 tRNAs transcribed in-between the 13 mtDNA-encoded proteins. 
Each of the twenty amino acids has its respective tRNA, while both serine and 
leucine have two tRNA copies. They are composed of 59 to 75 nucleotides. Table 
2.2 shows the translation table of mtDNA. Most of the genetic codes of human 
mtDNA are the same as the universal code, except UGA codes for tryptophan instead 
of termination, AUA codes for methionine instead of isoleucine, and AGA and AGG 
represent stop codons instead of arginine. The normal codon-anticodon pairing rules 
are more relaxed in mitochondria due to the small number of tRNA, many tRNA 
molecules can recognize any one of the four nucleotides in the third codon position. 
2.1.7 Displacement Loop 
The longest non-coding sequence in mtDNA is a control region called displacement 
loop (D-loop). It is present at nucleotide position from 16024 to 16569, then from 1 
to 576 with a molecular size of 1122 bp. It contains two hypervariable (HV) regions: 
HVl is from nucleotide position 16024-16383 and HV2 is from 57-372. There are 
three short regions called conserved sequence blocks (CSB) at 213-235, 299-315 and 
346-363 bp. They are GC rich sequence and are the most conserved element from S. 
cerevisiae to human (Chang et al., 1985). 
Although the D-loop region does not contain any coding genes, it is known to 
contain the origin of replication for H-strand synthesis as well as mitochondrial 
transcription promoters of both strands. It is the main initiation site for mitochondrial 
genomic replication and transcription (Taanman, 1999; Penta et al., 2001). Moreover, 
D-loop is a highly polymorphic region with high mutation rates. 
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57-372 MTHV2 Hypervariable segment 2 
110-441 MTOHR H-strand origin 
213-235 MTCSB1 Conserved sequence block I 
233-260 MTTFX mtTF1 binding site 
276-303 MTTFY mtTF1 binding site 
299-315 MTCSB2 Conserved sequence block II 
317-321 MTHPR Replication primer 
346-363 MTCSB3 Conserved sequence block III 
371-379 MTMT4H mt4 H-strand control element 
384-391 MTMT3H mt3 H-strand control element 
392-445 MTLSP L-strand promoter 
418-445 MTTFL mtTF1 binding site 
523-550 MTTFH mtTF1 binding site 
545-567 MTHSP1 Major H-strand promoter 
577-647 MTTF tRNA Phenylalanine (Phe) 
645-645 MTHSP2 Minor H-strand promoter 
648-1601 MTRNR1 12S rRNA 
1602-1670 MTTV tRNA Valine (Val) 
1671-3229 MTRNR2 16S rRNA 
3206-3229 MTRNR3 5S-like sequence 
3229-3256 MTTER Transcription terminator 
3230-3304 MTTL1 tRNA Leucine (UUR) (Leu) 
3305-3306 MTNC1 Non-coding nucleotides between MTTL1 and 
MTND1 
3307-4262 MTND1 NADH dehydrogenase 1 
4263-4331 MTTI tRNA Isoleucine (lie) 
4329-4400 MTTQ tRNA Glutamine (Glu) 
4401-4401 MTNC2 Non-coding nucleotide between MTTQ and 
MTTM 
4402-4469 MTTM tRNA Methionine (Met) 
4470-5511 MTND2 NADH dehydrogenase 2 
5512-5576 MTTW tRNA Tryptophan (Trp) 
5577-5586 MTNC3 Non-coding nucleotides between MTTW and 
MTTA 
5587-5655 MTTA tRNA Alanine (Ala) 
5656-5656 MTNC4 Non-coding nucleotide between MTTA and 
MTTN 
5657-5729 MTTN tRNA Asparagine (Asn) 
5721-5798 MTOLR L-strand origin 
5761-5826 MTTC tRNA Cysteine (Cys) 
5826-5891 MTTY tRNA Tyrosine (Tyr) 
5892-5903 MTNC5 Non-coding nucleotides between MTTY and 
MTC01 
5904-7445 MTC01 Cytochrome c oxidase 1 
7445-7516 MTTS1 tRNA Serine (UCN) (Ser) 
7517-7517 MTNC6 Non-coding nucleotide between MTTS1 and  
MTTD  
To be cont'd 
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7518-7585 MTTD tRNA Aspartic acid (Asp) 
7586-8269 MTC02 Cytochrome c oxidase II 
8270-8294 MTNC7 Non-coding nucleotides between MTC02 
and MTTK 
8295-8364 MTTK tRNA Lysine (Lys) 
8365-8365 MTNC8 Non-coding nucleotide between MTTK and 
MTATP8 
8366-8572 MTATP8 ATP synthase 8 
8527-9207 MTATP6 ATP synthase 6 
9207-9990 MTC03 Cytochrome c oxidase III 
9991 -10058 MTTG tRNA Glycine (Gly) 
10059-10404 MTND3 NADH dehydrogenase 3 
10405-10469 MTTR tRNA Arginine (Arg) 
10470-10766 MTND4L NADH dehydrogenase 4L 
10760-12137 MTND4 NADH dehydrogenase 4 
12138-12206 MTTH tRNA Histidine (His) 
12207-12265 MTTS2 tRNA Serine (AGU/C) (Ser) 
12266-12336 MTTL2 tRNA Leucine (CUN) (Leu) 
12337-14148 MTND5 NADH dehydrogenase 5 
14149-14673 MTND6 NADH dehydrogenase 6 
14674-14742 MTTE tRNA Glutamic acid (Glu) 
14743-14746 MTNC9 Non-coding nucleotides between MTTE and 
MTCYB 
14747-15887 MTCYB Cytochrome b 
15888-15953 MTTT tRNA Threonine (Thr) 
15925-499 MTATT Membrane attachment site 
15954-15954 MTNC10 Non-coding nucleotide between MTTT and 
MTTP 
15955-16023 MTTP tRNA Proline (Pro) 
16024-576 MTDLOOP Displacement loop 
16024-16383 MTHV1 Hypervariable segment 1 
16106-191 MT7SDNA 7S DNA 
16157-16172 MTTAS Termination-associated sequence 
16194-16208 MTMT5 Control element 
16499-16506 MTMT3L L-strand control element  
Table 2.1 
Locations of functional components in human mitochondrial genome (Accession 
number in GenBank: J01415) with descriptions on their names, nucleotide positions 
and abbreviations. 
Those rows shaded in gray are the 13 mitochondrial protein coding genes, those 
shaded in pink are two ribosomal RNA (rRNA) genes and those shaded in blue are the 
22 transfer RNA (tRNA) genes. The components in italics are transcribed from L-
strand (including eight tRNAs and ND6). 
(Modified from MITOMAP database: http://www.mitomap.org') 












































































































































































































































































































































































H H B I H I i l l i H I H t B I H 
Phenylalanine UUU Threonine ACU Aspartic acid GAU 
Phe UUC Thr ACC Asp GAC 
F T ACA D  ^  
Leucine UUA Alanine GCU Glutamic acid GAA 
Leu UUG Ala GCC Glu GAG 
L (UUA/G) A GCA E 
GCG  
Leucine CUU Tyrosine UAU Cysteine UGU 
Leu CUC Tyr UAC Cys UGC 
L (CUN) CUA Y C 
CUG 
Isoleucine AUU Termination UAA Tryptophan UGA 
lie AUC Ter UAG Tip UGG 
I ^  
Methionine AUA Histidine CAU Arginine CGU 
Met AUG His CAC Arg CGC 
M H R CGA 
CGG 
‘ Valine GUU Glutamine CAA Serine AGU 
Val GUC Gin CAG Ser AGC 
V GUA Q S (AGU/C) 
G I ^  
Serine UCU Asparagine AAU Termination AGA 
Ser UCC Asn AAC Ter AGG 
S (UCN) UCA N  
Proline CCU Lysine AAA Glycine GGU 
Pro CCC Lys AAG Gly GGC 
P CCA K G GGA  
CCG GGG 
Table 2.2 
The mitochondrial DNA genetic code (translation table). The three-letter and single-
letter abbreviations for each amino acid are indicated. 
Several genetic codes of mitochondrial DNA are changed from the universal codes, 
including UGA codes for tryptophan instead of termination, AUA codes for 
methionine instead of isoleucine, and AGA and AGG are terminators instead of 
coding for arginine (highlighted in blue). 
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2.2 Replication of Mitochondrial DNA 
Some of the components of mtDNA replication are present at the mitochondrial 
genome. The origin of H-strand replication (OH) is located downstream of L-strand 
promoter in the D-loop region, whereas the origin of L-strand replication (OL) is at 
two-thirds of the mitochondrial genome away from Oh. The replication round begins 
at Oh with the synthesis of a daughter H-strand and continues along the parental L-
strand to produce a full H-strand circle. After the replication fork has passed the 
second replication origin, OL, replication of the L-strand initiates which proceeds in a 
counter-clockwise direction to that of H-strand (Clayton, 1982; Taanman, 1999). 
Unlike nuclear DNA, mtDNA may replicate more than once during each cell cycle. 
The three evolutionary conserved sequence blocks at the D-loop, CSBI, II and II， 
have important functions in replication. They direct the precise cleavage of primary 
transcripts to provide the appropriate primer species and contribute to the formation 
of a persistent RNA-DNA hybrid, also termed the R-loop, leading to the initiation of 
mtDNA replication (Xu et al, 1995; Lee et al., 1998). Initially, replication of Oh at 
D-loop region produces RNA molecules. Transitions from RNA to DNA synthesis 
take place at several distinct sites (Taanman, 1999). Any change in the sequence of 
origin of replication and CSBs may lead to changes in mitochondrial proliferation. 
Transcription of Mitochondrial DNA 
Transcription of mtDNA requires promoters for H-strand and L-strand, which are 
about 150 base pairs apart. Major H-strand transcription starts at nucleotide position 
561 within the H-strand promoter (MTHSPl; information given in Table 2.1) and 
adjacent to tRNA-Phe gene. A second putative initiation site for H-strand (MTHSP2) 
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transcription is located around nucleotide position 638 in tRNA-Phe gene, adjacent 
to 12SrRNA gene. Its promoter region only shows limited similarity with 15-bp 
consensus sequence (5 '-CANACC(G)CC(A)AAAGAYA-3'), so it has a lower 
frequency than MTHSPl for H-strand transcription. 
Transcription of the L-strand starts at nucleotide position 407 located within the L_ 
strand promoter (MTLSP). Additional enhancer elements upstream to MTHSPs and 
MTLSP are required for optimal transcription. These elements are also known as 
transcription factor binding sites (mtTFls; Table 2.1). Transcription initiated at L-
strand promoter generates a RNA which remains firmly associated with DNA in the 
region defined by CSBs, displacing DNA strands to form a loop. Elongation of 
mlWA by RNA polymerase produces poly-cistronic molecules, because introns 
between genes are very short (1 to 25 bp). The attenuation of transcription is present 
at the transcription terminator (MTTER) right after the 16srRNA gene (Taanman, 
1999). Any change in promoter sequence may alter transcription of mtDNA. 
- 1 8 -
Section 3. Physiology of Mitochondria 
The main function of mitochondria is to generate energy through oxidative 
phosphorylation and control programmed cell death process called apoptosis. Urea 
synthesis occurs in a few tissues, including liver. The required enzymes are encoded 
in the nuclear genome and imported into mitochondria in these tissues (Alberts et aL, 
1994). 
3.1 Energy Production by Oxidative Phosphorylation 
(OXPHOS) 
Mitochondria are responsible for generating approximately 90% of cellular 
adenosine triphosphate (ATP) through oxidative phosphorylation process (Wallace, 
1997a; Penta et al., 2001). OXPHOS occurs within the inner membrane of 
mitochondria. It consists of five multi-subunit enzymatic complexes formed from 
approximately 74 nuclear genes and the 13 mitochondrial genes (Penta et al, 2001). 
Among them, mtDNA encodes seven of over 43 polypeptides of complex I，none of 
the four polypeptides of complex II, one of approximately 11 polypeptides of 
complex III，three of the 14 polypeptides of complex IV, and two of the roughly 15 
polypeptides of complex V (Information of the components can refer to Sections 
2.1.1 to 2.1.7). The mitochondrial polypeptides encoded by nuclear genome are 
translocated into the mitochondrial matrix space by passing through contact sites 
between inner and outer membranes. Translocation requires a specific signal peptide, 
driven by ATP hydrolysis and the electrochemical gradient across the inner 
membrane (Alberts et al, 1994). 
- 1 9 -
A simplified schematic diagram of OXPHOS is shown in Figure 3.1. Electrons are 
collected through two main pathways: (1) the electrons borne on nicotinamide 
adenine dinucleotide (NAD+) from various pathways are transferred to respiratory 
complex I (NADH dehydrogenase), then through a series of flavins and iron-sulfur 
centers to coenzyme Qio (CoQ). (2) The electrons from succinate in the tricarboxylic 
acid (TCA) cycle are transferred to succinate dehydrogenase (SDH) representing 
Complex II and then to CoQ. Next, the electrons in CoQ move through complex III 
(cytochrome bci-complex), cytochrome c, complex IV (cytochrome c oxidase, CO), 
and finally combine molecular oxygen to give water. The electron flow produces an 
electron transport chain (Wallace et al., 1998; Wallace, 1999). 
As electrons pass through complexes I，III and IV, protons are pumped out from the 
mitochondrial matrix to the intermembrane space, resulting in a transmembrane 
electrochemical gradient (A中m). It is positively charged and acidic on the outside 
and negatively charged and alkaline on the matrix side. This creates a capacitor 
effect and depolarization would occur when protons are transported back into the 
matrix through a proton channel in the FqFi membrane component of ATP synthase. 
The stored energy in the capacitor is utilized by ATP synthase as a source of 
potential energy for condensing adenine diphosphate (ADP) and inorganic phosphate 
to ATP. This ATP is transported across the mitochondrial inner membrane by the 
adenine nucleotide translocator (ANT) for providing energy in the organism. To 
conclude, oxygen consumed by the electron transport chain is coupled to ADP 
phosphorylation by the ATP synthase through the electrochemical gradient, A中m 
(Wallace et al, 1998; Wallace, 1999). 

































































































































































































































































3.2 Programmed Cell Death: Apoptosis 
Apoptosis is also called 'programmed cell death' process. Non-functional or harmful 
cells can be eliminated in response to a wide range of physiological and pathological 
signals. Mitochondria-mediated apoptosis plays a central role in animal development 
and tissue homeostasis, and its alteration results in a range of disorders including 
malignant cancers. 
Figure 3.2 shows a schematic diagram on apoptotic process. Several factors would 
initiate apoptosis, including excessive uptake of Ca2+ in mitochondria, increased 
exposure to ROS, or decline in energetic capacity. This promotes the opening of a 
nonspecific channel in the inner mitochondrial membrane, the mitochondrial 
permeability transition pore (mtPTP) (Petit et al., 1996; Green et al., 1998). 
The opening of mtPTP will cause the collapse of the electrochemical gradient, A^m. 
Swelling of the mitochondrial inner membrane will occur, follow by the release of 
death-promoting factors including cytochrome c (cyt c), apoptosis-inducing factor 
(AIF) and second mitochondria-derived activator of caspase (Smac) from the 
intermembrane space of mitochondria. Cytochrome c binds to apoptotic protease 
activating factor 1 (APAFl) in the presence of deoxy-ATP or ATP. The cytochrome 
c/APAFl complex then recruits procaspase-9 for autoactivation, followed by 
activation of caspases-3. Caspase-3 would execute a series of apoptotic events, like 
nuclear fragmentation and cellular breakdown in apoptotic vesicles cytoplasm. Bcl-2 
is a family of proteins localized in mitochondria or translocate from cytoplasm to 
mitochondria. It carries both apoptotic and anti-apoptotic roles to control the release 
of cytochrome c and Smac. 
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Both AIF and Smac were identified recently (Susin et al.，1999; Du et al., 2000). 
They are both produced in the cytosol and transported into mitochondria. AIF protein 
is a flavoprotein confined to the mitochondrial intermembrane space, which is acting 
as an oxidoreductase. It acts in a caspase-independent way beyond the Bcl-2 
controlled checkpoint of cell death and translocates through the outer mitochondrial 
membrane to the cytosol and then to the nucleus. The outcomes of AIF induction 
include chromatin condensation and large scale (approximately 50 kb) DNA 
fragmentation (Susin et al, 1999; Daugas et al, 2000). Smac promotes caspase 
activation the same way as that seen in the cytochrome c pathway. It is released into 
the cytosol during apoptosis and is controlled by Bcl-2 and inhibitor-of-apoptosis 
(lAP). Smac promotes caspase-9 activation by binding lAP and remove its inhibitory 
activity (Du et a/., 2000). 
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Figure 3.2 
A simplified schematic diagram of the apoptotic pathway. 
Detailed descriptions of the pathway are given in Section 3.2. 
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3.3 Morphology of Mitochondria in Hepatocytes 
Liver is called the 'body's chemical workshop', which is responsible for about 500 
metabolic processes in the body, such as metabolism of carbohydrates, lipids, amino 
acids and cholesterol; production of bile and plasma proteins, breakdown of 
hormones, storage of minerals and vitamins, detoxification, etc. Such a huge amount 
of metabolic processes must require a lot of energy. Approximately 2200 
mitochondria are found in each hepatocytes, which occupy about 18% of total cell 
volume (Stemieb, 1979). The size is generally larger than in other cells. 
Wu et al. has measured the size, number, and surface membranes of mitochondria in 
hepatocellular carcinoma associated with HBV, cirrhotic livers with and without 
HCC and alcoholic liver disease (ALD) (Wu et al., 1984). The mitochondria in HCC 
cells showed a significantly higher numerical density and surface density of internal 
membranes and cristae than mitochondria in the livers with cirrhosis and ALD. 
Another study also showed that there was an increase in the number of mitochondria 
with shorten cristae in well-differentiated HCC (Dominguez-Malagon et al., 2001). 
The metabolic activity of tissue is positively correlated with the number and size of 
mitochondria, as wells as the surface area and concentration of its cristae. These 
findings suggest an increased functional activity of mitochondria in HCC. 
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Section 4. Mutations of Mitochondrial DNA 
4.1 Special Terms Used in This Study 
4.1.1 Somatic Mutations and Polymorphisms 
Somatic cells are the cells in the whole body except germ cells or gametes of 
organisms. The mutation events occurred in the somatic cells during life of the 
organism is called somatic mutation. These mutations are not transmitted to future 
generations. Somatic mutations will have greater impact if they are dominant or if 
they are X-linked. Impact will be more noticeable if they occur early in development 
(Klug et al,, 1997). 
In contrast to somatic mutations, germ-line mutations are mutations that have existed 
in the previous generations and are inherited in the following generations. These 
mutations have generally existed in all human cells in an individual or a group of 
people and they are known as polymorphisms. Polymorphisms are useful in forensic 
medicine, in the construction of mtDNA phylogenies and the analysis of population 
migrations (Chinnery et al.，1999). 
4.1.2 Homoplasmic and Heteroplasmic Mutations 
Mitochondria containing only mutated or wild type DNA sequences are called 
homoplasmic. They have the same allelic structure, which is usually shared by all 
descendants of the same maternal lineage. The mutations found in these molecules 
are called homoplasmic mutations. For homoplasmic mutations, all tumor cells have 
the same variant haplotype. 
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The mtDNA molecules with the mutated sequences coexist with the wild-type 
molecules in the same cell, tissue or organ are called heteroplasmic. The mutations 
found in these molecules are called heteroplasmic mutations. Tumor cells being 
heteroplasmic contain a mosaic of inherited and acquired variant haplotypes. 
4.2 Factors Causing High Mutation Frequency in mtDNA 
The mutational rate of mtDNA is at least 10 times higher than that of nuclear DNA 
(Wallace, 1994). Some regions, like mitochondrial rRNA and tRNA sequences, can 
be 20- to 100-fold higher than nuclear DNA (Johnson et al., 2001a). There are 
several reasons for more obvious mutations in mtDNA than in nuclear DNA: 
presence of reactive oxygen species (ROS), lack of protective histones and limited 
DNA repair mechanisms. 
4.2.1 Presence of Reactive Oxygen Species 
Reactive oxygen species are molecular oxygen forms with enhanced chemical 
activity. Common ROS molecules include free radicals like superoxide radical (O2 一） 
and hydroxyl radical (OH •), or molecules with high oxidative power like hydrogen 
peroxide (H2O2). The chief source of ROS within the cell is solely mitochondria. 
ROS are generated by mitochondria as toxic by-products of oxidative 
phosphorylation. Electrons are accumulated in the early stages of the transport chain 
(complex I and CoQ). About 1 to 5% of them would lose their way (electron leakage) 
and donate to molecular oxygen directly to give superoxide anion, where most of the 
superoxide ions are produced in mitochondria (Wallace et al,, 1998). 
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MtDNA is located in the mitochondrial matrix, so it is close to the electron transport 
system (Penta et al., 2001). The free radicals in ROS produced in electron transport 
system would damage mitochondrial and cellular proteins, lipids and nucleic acids, 
including mtDNA. Acute exposure of ROS can inactivate the iron sulfur (Fe-S) 
centers of complexes I, II and III, and aconitase in tricarboxylic acid cycle, resulting 
in shutdown of mitochondrial energy production (Wallace, 1999). 
The first line of defense against superoxide is through an intramitochondrial free 
radical scavenging enzyme: superoxide dismutase (SOD). Manganese SOD (MnSOD) 
is one of the components with cofactor manganese. Superoxide anion is detoxified by 
MnSOD to give hydrogen peroxide (H2O2), and then converted to water by 
glutathione peroxidase (GPx) (Scheffler, 1999). Other enzymes involved in 
antioxidant defences include Se-containing gluathione peroxidase (Panfili et al., 
1991) and coenzyme Q (Forsmark et al,, 1991) 
Experimental results found that ROS, MnSOD and liver peroxidation products were 
raised in hepatoma cell lines (Okuda et al.’ 2002), while ROS production in liver 
tissue of transgenic mice had markedly increased (Hagen et al, 1994). This would 
strengthen the oxidative stress and damages in DNA before development of HCC. 
4.2.2 Lack of Protective Histones 
Histories are small protein molecules which is responsible for coiling the long DNA 
strands into short chromosomes. Negatively charged DNA strands bind onto 
positively charged histones, forming bead-like nucleosomes. Further coiling forms 
solenoids, loops and then a central scaffold, and finally to a supercoil chromosomal 
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structure. Histories can dissociate from DNA in replication process (Alberts et al, 
1994; Griffiths et a/., 2000). 
One of the properties for histories is to protect nuclear DNA from degradation. 
However, histories are not encoded in mitochondrial DNA or transported into the 
mitochondria. Therefore, mtDNA is vulnerable to be attacked by various chemical 
and biological agents like ROS discussed before. 
4.2.3 Limited DNA Repair Mechanism 
Three main kinds of repair systems in DNA: base excision repair, nucleotide excision 
repair and mismatch repair are discussed below. Other repair systems include direct 
repair to UV and carcinogens. 
Base excision repair: This can protect cells from endogenous DNA damage induced 
by hydrolysis, ROS and other intracellular metabolites. The repair is initiated by 
DNA glycosylases, which recognize and remove the damaged base by cleaving the 
N-glycosyl bond between the modified base and deoxyribose molecules, thus 
creating apurinic (AP) sites. Apurinic endonucleases then remove the 3，-deoxyribose 
moiety and generate a 3'-hydroxy 1 group for extension by DNA polymerase. The 
process is completed by DNA ligase rejoining the free DNA ends. (Seeberg et al” 
1995; Croteau et al., 1997; Croteau et al, 1999) 
Nucleotide excision repair: It is an important defense mechanism against two 
major carcinogens: sunlight and cigarette smoke. DNA damage is removed through 
incision of the damaged strand with 24-29 base pairs on both sides of the lesion, 
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followed by repair synthesis, which fills the gap using the intact strand as a template, 
and finally ligation. Sixteen polypeptides are involved in this process, including 
seven xeroderma pigmentosum proteins, the trimeric replication protein A, and the 
general transcription factor TFIIH (Sancar, 1996). 
Mismatch repair: DNA replication requires precise proofreading system because 
errors could introduce mutations to subsequent generations. Repetitive sequences 
like (C)n or (CA)n may be more prone to replication infidelity. The polymerase may 
slip under these circumstances, leading to chromosomes with either fewer or more 
copies of the repeat sequence. Examples of human mismatch repair (MMR) genes 
include hMSH2, hMLHl, hPMSl and hPMS2 (Parsons et al., 1993; Boyer et al, 
1995). These MMR genes can prevent slippage during the replication process. 
Although Saccharomyces cerevisiae possesses the mismatch repair homolog MSHl 
that can stabilize yeast mtDNA (Sia et al, 2000), the MSHl homologue was absent 
in higher eukaryotes (Habano et al.，1998; Longley et al, 2001). Therefore, it is 
uncertain whether an MMR system plays a role in human mtDNA maintenance. 
Moreover, nucleotide excision repair are deficient in mitochondrial genome (Bohr et 
al., 1985). The main mechanism for DNA repair in mtDNA is solely base excision 
repair (Sawyer et al., 1999). 
The DNA polymerase y is responsible for base excision repair in mitochondria. It 
includes a 140-kDa catalytic subunit which has high proofreading ability. Another 
55-kDa accessory subunit has been isolated (Carrodeguas et al., 2000). It has high 
processivity to the Pol y catalytic subunit, but the frameshift and base substitution 
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fidelity is greatly reduced (Longley et al., 2001). The replication error frequency 
(fidelity) of Pol y is in the range of 1 error in 1-20 million bases. This number is 
much lower than the overall fidelity in nuclear DNA, which is expected to be 1 in 1 
to IQIO bases (Johnson et al., 2001b). Therefore, the efficiency of Pol y in 
proofreading is relatively low. 
4.3 Theories of Homoplasmic Mutations 
4.3.1 Replicative Advantage on Mutated mtDNA Sequence ~ Clonal 
Selection 
When a mutation arises, a cell initially attains a heteroplasmy state with a mixture of 
wild-type and mutant mtDNAs. During cell division, the mutant and wild-type 
mtDNAs are randomly distributed into the daughter cells. Over many generations a 
replicative segregation state would occur as the mtDNA genotype of a cellular 
lineage can drift toward mutant or wild-type mtDNAs predominantly (Polyak et al.， 
1998;Fliss et al, 2000). 
The selective advantage presents as an ascending role. Homoplasmy in a mutant 
mitochondrial genome has a replicative advantage in a particular mitochondrion. 
This mitochondrion is selectively proliferated over other mitochondria in the same 
cell. Finally, a single tumor cell with mutated genome has a selective growth 
advantage during evolution of tumor, and it will become the predominant cell type in 
tumor cell population (Polyak et al., 1998). The selective advantage of mutated 
mtDNA over wild-type mtDNAs in successive divisions would lead to expansion of 
the transformed tumor cell. The functionally deficient mitochondrion with mutated 
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sequence would over-replicate to compensate its functional impairment (Bianchi et 
fl/.,2001). 
This theory has been proven by fusion experiments between two colorectal cancer 
cell lines. They investigated a T-to-C transition from two distinguished mtDNAs. 
After two months of culture, the originally balanced mtDNA mixture in the hybrids 
was changed to homoplasmy state, i.e. only one of the two parental genomes was 
present (Polyak et al., 1998; Kirches et al., 2001). 
Apart from classic clonal expansion described above, a 'pseudoclonal' selection was 
suggested by Fliss et aL It is a stochastic segregation of mitochondria with 
neoplastic clonal expansion by nuclear mutation. The mitochondrial genome having 
somatic mutation leads to produce a dominant genotype in mitochondrion. This 
mitochondrion can gain additional replicative advantage through nuclear influences. 
A mutated sequence gains a higher binding affinity to nuclear-encoded mitochondrial 
trans-acting factors. Because of its stochastic segregation together with the clonal 
expansion, mutated mitochondria overtake the entire population of tumor cells (Fliss 
etal, 2000). 
4.3.2 Random Mutagenesis and Segregation 
Coller et al. suggested that mtDNA mutations could arise entirely by chance in tumor 
progenitor cells. No physiological advantage or tumorigenic requirement is needed. 
The tumor progenitor cell achieves homoplasmy through unbiased mitochondrial 
replication and sorting during cell division (Augenlicht et aL, 2001; Coller et al., 
2001). 
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The mutant mtDNA copies are distributed between stem cells and transition cells, 
where the mutants are depleted (loss) or enriched (present), and the number of 
mutants in the lineage fluctuates as a random walk. The only stable conditions are 
loss of the mutant or homoplasmic mutations. Therefore, each of the mtDNA copies 
of the cell contains the same mutation (Coller et al, 2001). 
Their predicted model agrees with experimental data documenting the incidence and 
nature of tumor mitochondrial mutations. They found the predicted frequency of 
homoplasmy in tumor in absence of selection is similar to reported frequency of 
homoplasmic mutations. They thought there is no need to invoke a selective 
advantage for mutation (Coller et al, 2001). 
4A MtDNA Mutations in Mitochondrial Disease and Aging 
The first mitochondrial disease to be understood at molecular level was maternally 
inherited Leber's hereditary optic neuropathy (LHON), a sudden-onset blindness 
resulting from a mtDNA missense mutation. In Leigh's syndrome, patients may carry 
a T to G transition in the ATP6 gene that changes leucine at codon 156 to arginine. 
(Wallace et aL, 1988a) 
Protein synthesis mutations have been identified in multiple tRNAs. Two of the well 
known examples include myoclonic epilepsy and ragged red muscle fibers (MERRF) 
syndrome, caused by a base substitution from A to G at 8344 bp in tRNA-Lys 
(Wallace et al.，1988b); and in mitochondrial encephalomyopathy, lactic acidosis, 
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and stroke-like episodes (MELAS) syndrome, the A nucleotide at 3243 bp of tRNA-
Leu is changed to G (Wallace et al., 1996; Wallace, 1997b). 
Apart from base substitutions, various deletions and insertions were also discovered. 
MITOMAP，a database on the World Wide Web (http://www.mitomap.org), provides 
a lot of updated information on mitochondrial mutation and diseases. According to 
the recent data (December, 2001) over 145 mtDNA base substitutions, 96 deletions 
and a few insertions have been identified in a variety of degenerative diseases, 
neuromuscular diseases, diabetes and aging. 
During progression with life, there is a decline in OXPHOS enzyme activity and the 
accumulation of somatic mtDNA mutations in post-mitotic tissues. Heteroplasmic 
mutations, rearrangements and deletions occur and accumulate in skeletal muscles, 
cerebral cortex and basal ganglia of the brain after age 40-50 (Wallace et al., 1996; 
Wallace, 1997b). 
4.5 MtDNA Deletions in Cancer 
Followed by the discovery of mutations in degenerative disease and aging, 
researchers turned to determine the presence of somatic mutations in cancer patients. 
Firstly, large-scale deletion of mtDNA was found in various cancers by polymerase 
chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods. 
For example, a 4977-bp deletion was found in breast cancer and HCC (Fukushima et 
al., 1995)，and a 2583-bp deletion was found in colon cancer (Savre-Train et al, 
1992; Bianchi et al.，1995; Penta et al., 2001). These structural mtDNA alterations 
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may replicate as an incomplete mitochondrial genome, leading to transcription of 
truncated proteins. Even certain components for OXPHOS transcribed in 
mitochondrial genome would not be produced, leading to alteration of mitochondrial 
function. 
4.6 Somatic Mutations of MtDNA in Various Cancers 
In 1998，intensive somatic mutation study on the entire mitochondrial genome in 
colon cancer cell line was published (Polyak et al, 1998). In the past several years，a 
number of studies have been carried out on mtDNA mutations in different solid 
tumors, including bladder (Fliss et al.，2000)，brain (Kirches et al, 2001)，breast 
(Richard et al” 2000; Parrella et al.’ 2001; Tan et al； 2002), colon (Habano et al., 
1998; Polyak et al., 1998; Habano et al., 1999; Hibi et al； 2001b), esophagus (Hibi 
et al., 2001a), head and neck (Fliss et al.’ 2000), liver (Nishikawa et al, 2001; 
Nomoto et al., 2002), lung (Fliss et al, 2000; Sanchez-Cespedes et al.’ 2001), ovary 
(Liu et al” 2001), papillary thyroid (Yeh et al., 2000) and stomach (Tamura et al., 
1999; Habano et al., 2000). Table 4.1 illustrates a summary of these studies. In these 
studies, about 130 somatic mutation sites have been found in the 16.6kb mtDNA. 
The distribution of these sites (mutation spectrum) in terms of their position and 
changes in nucleotide or protein sequences are given in Table 4.2. 
4.6.1 Frequencies of Somatic Mutations 
The frequencies of mutations in various cancers are listed in Table 4.1. The 
percentage of cases with somatic mutations varied from 4% to 100%. This is because 
some of the studies did not cover the entire mitochondrial genome. However, if the 
calculation of somatic mutations only include those studies covered more than 80% 
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of the mitochondrial genome (studies highlighted in Table 4.1), the incidence rate 
would be more prevalent- ranging from 43% to 100%. Therefore, somatic mutations 
of mtDNA are frequent in various types of cancers. 
4.6.2 Distribution of Somatic Mutations in mtDNA 
The distribution of somatic mutation sites, including this study, is shown in Table 
4.2. The 130 somatic mutations sites can be found in 12 of the 13 coding genes (no 
mutation site was found in ATP8, which is the smallest gene in mtDNA), the two 
rRNAs and several tRNAs. By comparing the number of mutations and the size of 
the coding genes, more mutations can be found in 16S rRNA and ND5 genes, while 
fewer mutations are present in the three CO genes. Whether the distribution of 
mutations in these genes contribute to a common mechanism of cancer growth and 
development or the distribution simply represent a coincidence requires to be 
determined. 
The largest proportion of mutations is located in the 1.1 kb D-loop region 
(approximately 40%). Most of these somatic mutations are observed in the two 
hypervariable sites (HVl and HV2) and H-strand origin of replication. However, 
none was found in control element, L-strand control element, replication primer and 
major H-strand promoter. Moreover, there is a large difference in the frequency of 
somatic mutation sites found in the three conserved sequence blocks. Mutations were 
prevalent in the CSBII containing a poly-cytosine tract, while only one and no 
mutation site was found in CSBI and CSBIII. 
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Twenty-two mutation sites have been reported in more than one type of tumor 
(highlighted in yellow and green in Table 4.2). The nucleotide changes can be equal 
or different. Most of them (18) were present in the D-loop region. 
4.7 Somatic Mutations of Mitochondrial DNA in HCC 
To date, there are two reports that have analyzed alterations of mtDNA in HCC. The 
first was reported by Nishikawa et al in 2001 (Nishikawa et al., 2001). They 
compared the mtDNA sequences between tumor and non-tumor tissues in two HCC 
cases. Also included was the sequence analysis in part of the D-loop region (100 to 
600 bp) of 59 HCC patients. The number of mutations in D-loop in poorly, 
moderately and well differentiated HCC were analyzed. Compared with control liver 
tissue, they reported that the frequency of mtDNA mutations was markedly increased 
in both noncancerous and cancerous liver specimens from individuals with HCC. 
The second study was reported by Nomoto et al. in 2002 (Nomoto et al, 2002). They 
focused on the presence or absence of mutations in the D-loop region of each tumor 
in multicentric HCC and paired plasma samples were included for detecting of tumor 
DNA. They found that 13 of 19 HCC cases (68%) were identified as having D-loop 
mtDNA mutations in at least one tumor. In 3 of these 13 cases, the same mutation 
was observed in multiple tumors. Comparison of their results and ours will be 
discussed in Section 8.1. 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nucleotide m j ^ ^ ^ T u m o r Tvoe Reference 
^ ^ ^ Position Change Change Hetero  
D-loop 
41 C t o T N.A.4 N.S. Esophagus Hibi et al., 2001a 
60 T toG N.A. Homo Colon Hibi et al., 2001b 
70 G to A N.A. Homo Liver Nomoto et al.’ 2002 
66-71 DelG N.A. Homo Colon Hibi et al., 2001b 
72 T toC N.A. Homo Brain Kirches et al., 2001 
72 T toC N.A. Homo Liver Nomoto et al., 2002 
73 G to A N.A. Homo Breast Tan et al., 2002 
75 Gto A N.A. Homo Head and neck Fliss et al, 2000 
114 T toC N.A. Homo Bladder Fliss et al., 2000 
146 T t o C N.A. Homo Prostate Jer6nimo et al., 2001 
146 T toC N.A. Homo Ovary Liu etal., 2001 
150 C t o T N.A. Homo Lung Fliss et al., 2000 
^ T t o C ^ Homo Breast Tan et al., 2002 
T toC ^ Tlomo Ovary Liu et al., 2001 
152 C t o T N.A. Homo Breast Tan et al., 2002 
185 AtoG N.A. Homo Brain Kirches e/a/., 2001 
185 AtoG N.A. Homo Breast Tan et aL, 2002 
189 AtoG N.A. Homo Prostate Jer6nimo et al., 2001 
Gto A N ^ Homo Breast Tan et aL, 2002 
195 T t o C N.A. Homo Lung Fliss et al., 2000 
195 T t o C N.A. Homo Brain Kirches et aL, 2001 
195 C toT N.A. Homo Breast Tan et al., 2002 
199 T toC N.A. Homo Ovary Liu et al., 2001 
204 T toC N.A. Homo Prostate Jerdnimo et aL, 2001 
204 C t o T N.A. Homo Brain Kirches etal., 2001 
' m T toC Homo Breast Tan et al., 2002 
207 Gto A N.A. Homo Prostate Jeronimo et aL, 2001 
207 AtoG N.A. Homo Breast Tan et al, 2002 
235 AtoG N.A. Homo Prostate Jer6nimo et al., 2001 
249 Del A N.A. Homo Ovary Liu et al., 2001 
295 T toC N.A. Homo Brain Kirches et al., 2001 
303-3093 DelC N.A. Homo Bladder Fliss et aL, 2000 
303-309^ DelC N.A. Homo Head and neck Fliss et al., 2000 
303-309^ DelC N.A. Homo Lung Fliss et aL, 2000 
303-315 Ins Del n .a . Homo Breast Parrella er a/., 2001 
309 InsCCC N.A. N.S. Esophagus Hibi et al., 2001a 
303-309 Ins 1/2 C N.A. Homo Brain Kirches et al., 2001 
303-315 DeMbp^ins Homo Liver Nomoto et al., 2002 
303-309 1/2 C, Del ^.A. Homo / hetero Breast Tan etal., 2002 
386 Cto A N.A. Homo Bladder Fliss et al., 2000 
431 DelC N.A. Homo Liver Nomoto et al., 2002 
489 T toC N.A. Homo Ovary Liu et al., 2001 
514-525 Ins CA N.A. Homo Head and neck Fliss et al., 2000 
514-525 Ins(CA)2 N.A. Homo Brain Kirches e/ aL, 2001 
16093 C t o T N.A. Homo Breast Parrella a/., 2001 
16108 C t o T N.A. Homo Colon Hibi et aL, 2001b 
16126 C t o T N.A. Homo Brain Kirches et al., 2001 
16134 C t o T N.A. Homo Brain Kirches et al., 2001 
16147 C t o T N.A. Hetero Breast Tan et al., 2002 
16172 C t o T N.A. Homo Head and neck Fliss et aL, 2000 
16172 C t o T N.A. Homo Breast Tan etal., 2002 
16182 A t o C N.A. Hetero Breast Tan et al., 2002 
16183 Cto A N.A. Homo Lung Fliss et al., 2000 
16187 C t o T ^ Homo l^ng Fliss et al., 2000 
To be cont'd 
-40 -
16189 InsT ^ Homo Bladder Fliss et aL, 2000 
16189 C t o T N.A. Hetero Breast Tan et al., 2002 
16184-16193 Ins C/ Del C N.A. Homo Brain Kirches et al, 2001 
16209 C t o T N.A. Homo Liver Nomoto et al., 2002 
16222 C t o G N.A. Homo Colon Hibi et al., 2001b 
16265 A t o C N.A. Homo Bladder Fliss et aL, 2000 
16278 T t o C N.A. Homo Ovary Liu et al, 2001 
16278 T t o C N.A. Homo Liver Nomoto a/^2002 
16292 C to T NA. Homo Head and neck Fliss et al, 2000 
丄6292 ^ t o j； N.A. Homo Breast Parrellae丄 a/^2001 
一 16293 " X t o G S X Homo Brain Kirches et al, 2001 
16293 A t o G N.A. Hetero Breast Tan et al, 2002 
16294 C t o T N.A. Homo Colon Hibietai , 2001b 
16300 A t o G N.A. Homo Head and neck Fliss et al., 2000 
16325 C t o T N.A. Homo Breast Tan et al., 2002 
16356 T t o C N.A. Homo Brain Kirches et al., 2001 
16362 T t o C N.A. Homo Breast Tan et al., 2002 
16365 C t o T N.A. Homo Ovary Liu et al., 2001 
16365 C t o T N.A. Homo Breast Tan et al., 2002 
16380 Gto A N.A. Homo Lung Fliss et al., 2000 
16390 Gto A N.A. Homo Liver Nomoto et al, 2002 
16519 T t o C N.A. Homo Lung Fliss et al., 2000 
16519 T t o C N.A. Homo Brain Kirches e/a/., 2001 
16519 T t o C N.A. Homo / hetero Breast Tan et al, 2002 
16532 A t o T N.A. Homo Bladder Fliss et al., 2000 
12S rRNA 
664 Gto A N.A. Homo Ovary Liu et al., 2001 
710 T t o C N.A. Homo Colon ？o\yaketal., 1998 
1401 Gto A N.A. Homo Ovary Liu et al., 2001 
16S rRNA 
1738 T t o C N.A. Homo Colon ？o\yaketal., 1998 
1811 A t o G N.A. Homo Head and neck Fliss et al., 2000 
1811 A t o G N.A. Hetero Breast Tan et aL, 2002 
1952 T t o C N.A. Homo Ovary Liu et al, 2001 
1967 T t o C N.A. Hetero Colon Polyake/a/., 1998 
2056 Gto A N.A. Hetero Bladder Fliss et al, 2000 
2299 T t o A N.A. Hetero Colon Polyake/a/., 1998 
2445 T t o C N.A. Homo Bladder Fliss et al., 2000 
2664 T t o C N.A. Homo Lung Fliss et al., 2000 
2805 A t o T N.A. Homo Pancreas Jones et al., 2001 
2923 Gto A N.A. Homo Prostate Jer6nimo et al., 2001 
3054 Gto A N.A. Hetero Bladder Fliss et al., 2000 
tRNA-Leu 
3244 Gto A N.A. Hetero Gastric Habano et al., 2000 
NDl 
3308 T t o C Met to Thr Homo Colon ？olyaketaL, 1998 
3380 Gto A ArgtoAln Homo Colon Habano etal., 1999 
3418-3432 Del 15 bp Homo Colon Habano etal.,\999 
3566-3571 InsC Stop Hetero Colon Habano et al., 1998 
3670 Gto A Ala to Thr Homo Pancreas Jones et al., 2001 
3918 Gto A GlutoGlu Homo Breast Parrella et al., 2001 
NDl 
4646 T t o C Tyr to Tyr Homo Brain Kirches et al., 2001 
4973 C t o T GlytoGly Homo Breast Tan et al., 2002 
4973 T t o C GlytoGly Homo Breast Tan et al., 2002 
5198 A t o G Leu to Leu Homo Brain Kirches et al, 2001 
5285 Gto A Lys to Lys Homo Breast Tan et al., 2002 
tRNA-Trp 
5521 Gto A N.A. Homo Lung Fliss et al, 2000 
COI 
5999 T t o C Ala to Ala Homo Brain Kirches et al., 2001 
To be cont'd 
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6047 A t o G Leu to Leu Homo Brain Kirches et al., 2001 
6264 Gto A Gly to Stop Homo Colon Polyake/a/., 1998 
tRNA-Asp 
7521 Gto A N.A. N.S. Yeh etal., 2000 
thyroid 
coil 
8009 Gto A Val to Met Homo Colon Polyak et al., 1998 
ATP6 
9131 T t o C Leu to Pro Homo Breast Tan et al., 2002 
coin 
9949 Gto A Val to He Homo Colon Polyak et al., 1998 
ND3 
10071 T t o C Leu to Leu Homo Bladder Fliss et al., 2000 
10321 T t o C Val to Ala Homo Bladder Fliss et al., 2000 
10398 A t o G Thr to Ala N.S. Yeh etal., 2000 
thyroid 
ND4L 
10563 T t o C Cys to Arg Homo Colon Polyak et al., 1998 
ND4 
10792 A t o G Leu to Leu Homo Bladder Fliss et al, 2000 
10793 C t o T Leu to Leu Homo Bladder Fliss et al, 2000 
10822 C t o T His to His Homo Bladder Fliss etal., 2000 
10822 C t o T His to His Homo Head and neck Fliss et al., 2000 
10978 A t o G Leu to Leu Homo Bladder Fliss et al., 2000 
11065 A t o G Leu to Leu Homo Bladder Fliss et al., 2000 
11150 Gto A Ala to Thr Homo Head and neck Fliss et al., 2000 
11518 Gto A Leu to Leu Homo Bladder Fliss et al., 2000 
11900 Gto A Val to Met Homo Breast Parrella et al., 2001 
12049 C t o T Phe to Phe Homo Bladder Fliss et al., 2000 
tRNA-Leu 
12300 Gto A N.A. Hetero Lung El Meziane et al., 1998 
ND5 
12344 Tto A Met to Lys Homo Breast Parrella et al., 2001 
12345 Gto A Met to Met Homo Lung Fliss et al., 2000 
12385-12390 Del C Stop Homo Colon Habanoe/a/., 1998 
12418-12425 Ins A Stop Homo Colon Polyak era/., 1998 
12418-12425 Ins A Stop Homo Colon Habano etal., 1998 
12519 T t o C Val to Val Homo Bladder Fliss et al., 2000 
12936 A t o G Gin to Gin Homo Brain Kirches et al., 2001 
13124 T t o C Phe to Ser Homo Brain Kirches et al., 2001 
13393 Gto A Glu to Lys Hetero Colon Habano etal., 1999 
13708 Gto A Ala to Thr Homo Breast Parrella e/ al., 2001 
ND6 
14603 Gto A Ser to Phe Homo Pancreas Jones et al., 2001 
14620 C t o T Gly to Gly Homo Brain Kirches et al., 2001 
CYB 
14798 C t o T Leu to Phe Homo Brain Kirches et al., 2001 
14869 Gto A Leu to Leu Homo Breast Parrella et al., 2001 
14985 Gto A Arg to His Homo Colon Polyak era/., 1998 
15179 Gto A Val to Met N.S. ^thyr^ Y^h etal., 2000 
15572 T t o C Phe to Leu Homo Colon Polyak a/., 1998 
15642 Del21bp Del^^^ ino Homo Bladder Fliss eM / .�2000 
15761 Gto A N.A. Hetero Ovary Liu et al, 2001 
tRNA-Pro 
15983 T t o C N ^ Homo Pancreas Jones et al, 2001 
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Table 4.2 
The somatic mitochondrial DNA mutation sites found in various tumor studies. 
Those mutation sites not stated clearly are not included. Mutation sites found in more 
than one type of cancer are highlighted. Those highlighted in green carries the same 
nucleotide change in different studies. Yellow highlights indicate that the nucleotide 
change is different. The full names of protein can be found in the translation table of 
mtDNA (Table 2.2) 
Footnotes: 
1: Nucleotide positions highlighted in red represent nucleotide repeat sequences. 
More information is given in Section 8.5. 
2: Abbreviations: Hetero: heteroplasmic mutation; Homo: homoplasmic mutation. 
The authors categorized homoplasmy as the mutations detected were 
homoplasmic or nearly homoplasmic. N.S. represents the authors did not state the 
mutation were homoplasmic or heteroplasmic. 
3: The author of the article reported the C deletion occurred in 302 bp. However, it is 
known that 302 bp is an A nucleotide. Therefore, it is believed that the deletion 
represented the C deletion in the poly-C tract from 303 to 309 bp. 
4: Abbreviation: N.A.: The protein changes are not applicable as they represent 
rRNAs, tRNAs, or non-coding sequences. 
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Section 5. Objectives of This Study 
Liver is an organ with a large number of metabolic processes and thus the amount of 
energy required is large. The size and number of mitochondria in the liver are 
relatively larger than other organs. During development of HCC, the morphology of 
mitochondria is altered. The production of ROS through the electron transport chain 
may damage the mtDNA and the poor defense mechanisms against mutations and 
removal of ROS would accumulate somatic mutations and aberrations. As mtDNA 
has a large copy number, homoplasmic mutations could exist due to clonal selection 
theory. 
After the complete sequence of mitochondrial genome was published, it was 
suggested that mtDNA mutations were found in various degenerative diseases and 
aging (Section 4.4). Later on, large-scale deletions of mtDNA had been found in 
several cancers (Section 4.5) (Savre-Train et al., 1992; Bianchi et al., 1995; Penta et 
al., 2001). In 1998, Polyak et al published a study on somatic mtDNA mutation in 
colon cancer cell line (Polyak et al., 1998) followed by more reports on various 
cancer types in the past few years (Section 4.6). 
The objectives of this study are: 
(1) To investigate the presence and frequency of somatic mtDNA mutations 
in HBV-infected hepatocellular carcinoma in the Chinese population by 
sequence analysis of the entire mitochondrial genome in ten HCC cases 
and their corresponding non-tumor tissues; 
(2) To compare the frequencies and distribution of these somatic mutation 
sites with previous studies on HCC and various other tumors; 
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(3) To establish whether there is a relationship between the pathogenesis of 
HCC associated with chronic HBV infection and the sequence changes in 
mitochondrial genome through sequence analysis of mtDNA from 
matched lymphocytes; 
(4) To detect the presence of somatic mutations in tumor DNA from serum of 
the same cohort by automated sequencing method and determine whether 
serum from HCC patients could be used for detecting mutations, for non-
invasive diagnosis of HCC; 
(5) To determine the presence of any potential marker(s) in HCC by 
evaluating the mutation frequencies in two nucleotide repeat sites (poly-
cytosine tract at 303-315 bp and CA repeat at 514-525 bp). A total of fifty 
HCC samples were included for sequencing analysis. The significance of 
potential marker(s) in diagnostic use was also determined; and 
(6) To determine whether the presence of somatic mutations in poly-cytosine 
tract may be a genetic prognostic marker in HCC by carrying out survival 
analysis using Kaplan-Meier method and Cox regression proportional 
hazard model. 
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Section 6. Materials and Methods 
Figure 6.1 is a flowchart illustrating the experimental methods used in sequence 
analysis of mitochondrial genome. 
6.1 Patients and Samples Collection 
Ten fresh liver specimens with HCC were obtained immediately after partial 
hepatectomies from the Department of Anatomical and Cellular Pathology at Prince 
of Wales Hospital in Hong Kong between the years 1998 and 2000. These HCC 
specimens and their surrounding non-tumor liver tissues near resection margin were 
collected and diagnosed histopathologically to have chronic HBV infection. With the 
exception of small areas of necrotic cells, nearly all sections were comprised of > 
85% neoplastic cells. Two normal liver samples from liver transplant donors were 
also included (obtained in 1995 and 1998) as controls. All the liver specimens were 
immediately frozen in liquid nitrogen and stored in a -85°C refrigerator before DNA 
extraction. The clinical information of the ten patients (cases d04 to d09, dl2 to dl5) 
was shown on Table 6.1. Blood samples from the patients were collected by the 
Department of Surgery, the Chinese University of Hong Kong. Details of the 
experiments were stated in Sections 6.8.1 and 6.8.2. 
In another part of the study, the paired tumor and non-tumor tissues in 50 HCC 
patients (including the ten patients in the entire genome analysis) from the year 1993 
to 2001 were included for examining the presence of mutations in two nucleotide 
repeat sequences. Details of the experiment were stated in Section 6.8.3, and the 
clinical data of the patients (cases dOl to d60) is provided in Table 6.2 and Section 
6.9. 
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Figure 6.1 
A simplified flowchart showing the strategies and methods used in this study. 
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Largest I 
Case Presence of Hepatitis Stage of Occurrence of Recurrence Death Survival 
Age Sex Diameter 
No. Cirrhosis Status DifTerentiation Recurrence (Days) Status (Days) 
(cm) 
dOl 44 M 2.5 Y HBV+ve Well No 429 Alive 429 
d02 56 M 4.0 Y HBV+ve Moderate No 67 Died 67 
d03 50 M 6.0 Y HBV+ve Moderate Yes 83 Died 116 
d04 52 M 4.5 Y HBV+ve Moderate Yes 175 Died 418 
d05 65 F 6.2 Y HBV+ve Moderate No 144 Died 144 
d06 44 F 2.7 N HBV+ve Moderate No 1247 Alive 1247 
d07 59 M 3.0 Y HBV+ve Well Yes 458 Alive 503 
d08 43 M 8.3 N HBV+ve Moderate Yes 138 Died 237 
d09 43 M 1.8 Y HBV+ve Moderate No 143 Died 143 
dl2 58 M 4.5 N HBV+ve Poor Yes 348 Died 450 
dl3 37 M 6.9 N HBV+ve Poor Yes 282 Died 808 
dl4 72 M 2.4 Y HBV+ve Moderate No 829 Alive 829 
dl5 63 M 11.5 N HBV+ve Moderate Yes 335 Died 461 
d21 64 M 3.3 Y HBV+ve Moderate No 43 Died 43 
d22 48 M 8.0 N HBV+ve Moderate Yes 197 Died 215 
d23 67 M 6.5 Y HBV+ve Moderate No 386 Alive 386 
d24 67 F 2.8 Y HBV+ve Well No 316 Alive 316 
d25 68 M 2.0 N HBV+ve Moderate No 349 Alive 349 
d26 70 M 5.5 N HCV+ve Moderate Suspected 8 Alive 297 
d27 65 M 4.2 Y HBV+ve Moderate No 156 Alive 156 
d28 56 M 2.2 Y HBV+ve Well No 5 Died 5 
d29 50 M 5.8 N HBV+ve Moderate Yes 386 Alive 1011 
d30 44 M 6.0 N HBV+ve Moderate Yes 229 Died 506 
d33 74 M I.M. N HBV+ve Moderate Suspected 456 Alive 505 
d34 57 M 4.0 Y HBV+ve Poor No 357 Died 357 
d35 50 M 3.0 N HBV+ve Moderate Yes 194 Died 362 
d36 42 M 4.0 N HBV+ve Moderate Yes 374 Died 1663 
d37 17 M 5.0 N HBV+ve Moderate Yes 885 Died 1443 
d38 59 M 5.5 Y HBV+ve Moderate No 3 Died 3 
d39 69 F 7.5 Y HBV+ve Well No 48 Died 48 
d40 75 F 2.4 Y HBV-ve Moderate No 2024 Alive 2024 
d41 67 M 4.0 Y HBV+ve Moderate Yes 461 Died 726 
d42 43 M 4.5 Y HBV+ve Moderate Suspected 1741 Alive 2297 
d43 54 M 8.0 N HBV+ve Moderate No 81 Died 81 
d44 54 M 2.5 Y HBV+ve Moderate Yes 76 Died 650 
d45 62 F 2.0 Y HBV-ve Moderate No 10 Died 10 
d46 40 M 8.5 Y HBV+ve Moderate No 91 Died 91 
d47 35 M 3.5 Y HBV+ve Moderate Yes 149 Died 542 
d48 60 M 4.7 Y HBV+ve Well Yes 702 Died 1431 
d49 62 M 11.0 Y HBV+ve Well No 24 Died 24 
d50 68 F 8.0 Y HBV+ve Moderate Yes 152 Died 212 
d51 54 F 11.0 N HBV-ve Moderate No 2613 Alive 2613 
d52 46 M 7.5 N HBV+ve Moderate Yes 80 Died 293 
d54 71 M 14.0 N HBV+ve Moderate Yes 108 Died 110 
58 M 3.0 Y HBV+ve Wei 丨 Yes 1415 Died 1420 
To be cont'd 
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r°d56 40 F 3.0 Y HBV+ve Moderate ^ 95 D i ^ 95 
d57 62 M 5.5 N HBV+ve Well No 1398 Alive 1398 
d58 58 F 2.5 N HBV+ve Well No 1388 Alive 1388 
d59 53 M 5.0 N HBV+ve Moderate Yes 278 Died 747 
d60 45 M 3.5 Y HBV+ve I.M. No 1795 Alive 1795 
Table 6.1 
Clinical data of the 50 patients in sequence analysis. 
Cases d04 to dl5 were applied for sequencing analysis of the whole mitochondrial genome 
and all 50 cases (dOl to d60) were included for analyzing two nucleotide repeat sequences. 
Abbreviation: I.M.: Information missing for this case. 
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6.2 DNA Extraction from Liver Tissues 
Large molecular weight genomic DNA from the liver tissue was isolated by 
Genomic-tip 100/G DNA Extraction Kit (Qiagen, Hilden, Germany). The tip 
contains a small column packed with anion-exchange resin. Under different salt 
concentrations and pH conditions, impurities including RNA and protein are 
removed and genomic DNA is eluted in a high-salt buffer. 
Eighty to one hundred milligram of frozen tissue were used for extraction. Tissue 
from each case was thoroughly homogenized by razor blade on ice and then 
transferred to a 50 ml-centrifugate tube with 9.5 ml lysis buffer and ribonuclease A 
(200 i^g/ml). 500 \i\ of proteinase K (Img/ml; Sigma, St. Louis, MO) was added and 
the tissue was digested at 50�C. The Genomic-tip was equilibrated with 4 ml Buffer 
QBT and was allowed to be empty by gravity flow. The digested tissue was 
centrifuged at 3500 x g for 20 minutes. The supernatant was transferred to a new 
centrifuge tube and was vortexed for 10 seconds to prevent clogging of the tip. The 
tip was washed twice with 7.5 ml Buffer QC followed by elution of genomic DNA 
with 5 ml of Buffer QF. The extracted DNA was precipitated with 3.5 ml of 
isopropanol followed by centrifugation at 3500 x g for 20 minutes. The pellet of 
DNA was transferred to a microcentrifuge tube and washed by 1.0 ml of 70% cold 
ethanol for two times with 10-minute centrifugation at maximum speed. The DNA 
was finally resuspended in 200 \i\ IX Tris ethylenediaminetetraacetic acid (EDTA) 
buffer (TE buffer, pH 8.0). 
The purity and concentration of DNA were measured by Ultra Violet 
spectrophotometer (Beckman Instruments, Inc., Fullerton，CA). The purity of DNA 
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was determined by the ratio of absorbance at 260 nm to absorbance at 280 nm, which 
falls within 1.7 to 1.9. A portion of the DNA was diluted to the concentration of 
about 100ng/|al and stored at -20°C for future studies. 
6.3 Amplification of Mitochondrial DNA by Polymerase 
Chain Reaction 
6.3.1 Design of Primers 
The analysis of the complete mitochondrial genome was determined by ten large 
segments, with size ranging from 871 to 2608 base pairs. Some nuclear pseudogenes 
recognizing mitochondrial genome had been identified (Parfait et al., 1998). As they 
have about a few hundred bp in size, amplifying PGR fragments of mtDNA with a 
larger size can prevent amplification of nuclear pseudogenes. 
In the 10 pairs of primers, half of them were obtained from previous papers written 
by Polyak et al., 1998 and Fliss et al, 2000, and the other were obtained from the 
Primer 3 Software (Whitehead Institute for Biomedical Research, MIT Center for 
Genome Research). These primers were produced by Gibco, Invitrogen (Tokyo, 
Japan) and their sequences were listed in Table 6.2. 
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Forward (F) I Sequence 
Name Primer Sequence (5' to 3') 
Reverse (R) Range 
Fragment 1 (871 bp) 
~MTDLPC F 71-90 GTATGCACGCGATAGCATTG 
MTDLPE^ F 321-340 TGGCCACAGCACTTAAACAC 
MT12SD R 941-922 CTTTACGCCGGCTTCTATTG 
Fragment 2 ( 2 3 7 5 bp) 
~MT12SA F 822-843 GATTAACCTTTAGCAATAAACG 
MT12SB F 1320-1340 GACGTTAGGTCAAGGTGTAGC 
MT16SC F 1831-1852 GACTAACCCCTATACCTTCTGC 
MT16SD F 2314-2334 CATGAAAACATTCTCCTCCGC 
MT16SA R 3217-3198 TGGGTGGGTGTGGGTATAAT 
Fragment 3 (1522 bp) ‘ 
~MTNADIA F 3017-3036 CAGCCGCTATTAAAGGTTCG 
MTNADIB F 3488-3507 TAAAACCCGCCACATCTACC 
MTNADIC R 4538-4519 GCTTAGCGCTGTGATGAGTG 
Fragment 4 (2071 bp) 
“MTNAD2A F 4430-4450 CCCATACCCCGAAAATGTTGG 
MTNAD2B F 4946-4966 CTTATCCATCATAGCAGGCAG 
MTTRPA F 5521-5542 GGTTAAATACAGACCAAGAGCC 
MTCOXIA R 6500-6478 GAGAGATAGGAGAAGTAGGACTG 
Fragment 5 (1893 bp) 
MTCOXIB F 6478-6500 CAGTCCTACTTCTCCTATCTCTC 
MTCOXIC F 6959-6979 CCTGACTGGCATTGTATTAGC 
MTC0X2A F 7401-7419 CCACCCTACCACACATTCG 
MTC0X2B R 8370-8349 GGCATTTCACTGTAAAGAGGTG 
Fragment 6 (1927 bp) 
""“MTATP8A F 8107-8126 AATTCCCGGACGTCTAAACC 
MTATP6A F 8646-8665 CCGACTAATCACCACCCAAC 
MTC0X3A F 9120-9139 ACTGACTATCCTAGAAATCG 
MTNAD3B R 10033-10012 CTAGTTAATTGGAAGTTAACGG 
Fragment 7 (2608 bp) 
MTNAD3A F 10027-10047 TAACTAGTTTTGACAACATTC 
MTNAD4 D F 10465-10484 ACCAAATGCCCCTCATTTAC 
MTNAD4A F 10755-10775 CTCCAATGCTAAAACTAATCG 
MTNAD4C F 11255-11275 TACACTCACAACACCCTAGGC 
MTNAD4B F 11512-11533 CCCCCTGACAAAACACATAGCC 
MTNAD5A R 12634-12613 TGGACCATGTAACGAACA?^TGC 
_ 5 2 - To be cont'd 
Fragment 8 (1907 bp) "“ 
MTNAD5B F 12546-12564 AACCCAAACAACCCAGCTC 
MTNADSE^ F 13332-13351 CGCCTTCTTCAAAGCCATAC 
MTNAD5C R 13436-13417 GGTATGGTTTTGAGTAGTCC 
MTNAD6C'^ F 13835-13855 CAGCCCTAGACCTCAACTACC 
MTNADSD^ R 13958-13939 CCTAGATAGGGGATTGTGCG 
MTNAD6A'^ R 14452-14432 TATTGAGGAGTATCCTGAGGC 
Fragment 9 (948 bp) 
MTNAD6B F 14357-14376 ACCCACAGCACCAATCCTAC 
MTCYBB R 15304-15285 GGGCAAGATGAAGTGAAAGG 
Fragment 10 (1723 bp) “ 
MTCYBA F 15196-15216 ATCCGCCATCCCATACATTGG 
MTCYBC F 15613-15632 AGGCGTCCTTGCCCTATTAC 
MTDLPF^ F 16231-16251 TCACACATCAACTGCAACTCC 
MTDLPD R 16422-16403 ATTGATTTCACGGAGGATGG 
MTDLPA R 349-327 GGCAGAGATGTGTTTAAGTGCTG 
Table 6.2 
Nucleotide position and sequence of primers for PCR^ and sequencing reaction. 
Information of primers is provided by Polyak et al., 1998, Fliss et al., 2000 and 
Primer 3 Software (Whitehead Institute for Biomedical Research, MIT Center for 
Genome Research). 
Footnotes: 
1: The ten pairs of primers for PCR are the first and last primers indicated in each 
fragment. 
2: Primers MTDLPE and MTDLPF were applied for cases d05T, d05N and dl5T. 
As mixed population of sequence occurred near 310 bp when using the original 
primer (MTDLPC) for sequening, ambiguous sequencing data would be produced 
form 310 bp onwards. Therefore, primer MTDLPE was applied for reading the 
sequence from 321 bp onwards. 
3： Primer MTNAD5E was applied to substitute MTNAD5D in some cases where the 
sequence reading using MTNAD5D was unsatisfactory. The result was greatly 
improved by reading the sequence in the opposite direction using MTNAD5E. 
4： Primer MTNAD6C was applied to substitute MTNAD6A, same reason as stated 
in 3. 
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6.3.2 PCR Conditions and Contents 
PCR reaction mixture contained 50-200 ng of genomic DNA (about 1 ^1), 2.5 |LI1 of 
lOX PCR Buffer with 100 mM Tris-HCl and 500 mM KCl (Applied Biosystems, 
Foster City, CA), 6.7 |li1 of 25 mM MgCb, 1.5 |iil dimethyl sulfoxide (DMSO), 1.5 i^l 
of 25 mM dNTPs, 1 )il of 12.5 \iM each of the forward and reverse primer and 1.25 
units of AmpliTaq Gold (Applied Biosystems, Foster City, CA). The total volume 
was made up to 25 \il PCR was carried out in the PTC-100 Thermo Cycler (MJ 
Research, Waltham, CA) with the following protocol: 95°C for 10 min, followed by 
35 cycles of 95°C for 55 sec, 55°C for 1.5 min, 72°C for 3.5 min and final extension 
of 72°C，10 min. DMSO was a co-solvent to facilitate the amplification of PCR from 
different templates (Pomp et al., 1991). 
6.3.3 Assessment of PCR Products by Agarose Gel Electrophoresis 
Assessment of the PCR products was carried out by 0.7% agarose gel (Sigma, St. 
Louis，MO) with staining of ethidium bromide. The loading mixture contained 1 \x\ 
of 6X loading dye (MBI Fermentas, Hanover, MD) and 5 |LI1 of PCR products. The 
product sizes were assessed by lEcolSOI (Styl) ladder. The electrophoresis was 
carried out in IX Tris borate EDTA (TBE) buffer at 120 volts for 20 minutes and 
was visualized and photographed under UV illumination. 
6.4 Purification of PCR Products 
The amplified DNA fragments were purified by High Pure PCR Product Purification 
Kit (Roche Applied Science, Mannheim, Germany). The glass fibers pre-packed in 
-54 -
filter tube would selectively bound the desired DNA, removing the unincorporated 
nucleotides, primers, mineral oil, salts and thermostable polymerase. 
The protocol had several adjustments compared to that of the manufacturer. Firstly, 
250 \il of binding buffer with chaotropic salt guanidine thiocyanate was added to the 
tube with PGR reaction mixture. They were then transferred to the upper reservoir of 
the filter tube inserted into a collection tube, followed by 1-minute centrifugation at 
13,000 X g in a table top centrifuge at room temperature. Four hundred )j,l of wash 
buffer was added to the upper reservoir, then with 1-minute centrifugation at the 
same speed. The washing step was repeated once by adding 200 of wash buffer 
and centrifuged for 2 minutes. Finally, the purified DNA (template) was eluted with 
30 to 50 |Lil elution buffer and centrifuged for 1.5 minutes. The template was stored in 
-20°C for further analysis. 
6.5 Cyclesequencing of Mitochondrial DNA 
6.5.1 Design of Primers 
There were totally 42 primers (including the 20 primers for PGR) for sequencing 
reaction. The primer sequences were obtained from previous papers (Polyak et al., 
1998; Fliss et aL, 2000)，and through the Primer 3 Software (Whitehead Institute for 
Biomedical Research, MIT Center for Genome Research). Table 6.2 showed the 
nucleotide position of the sequences. 
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6.5.2 PGR Contents and Cycle Sequencing Procedures 
Cycle sequencing reaction was performed with BigDye Terminator Cycle 
Sequencing Ready Reaction Kit Version 2.0 (Applied Biosystems, Foster City, CA). 
It contained all components required for sequencing reaction (ddNTP, dNTP, 
AmpliTaq Gold, reaction buffer) except templates and primers. The reaction mix 
contained a mixture of fluoroscent dyes link to different ddNTPs. In every 5.0 i^l of 
reaction mixture, there was 0.5 |LI1 of 4 |aM primer, 2.5 of purified DNA and 2.0 jul 
of terminator ready reaction mix. Sequencing reactions were cycled for 35 cycles at 
96�C for 30 sec, 50�C for 20 sec and 60°C for 4 min, with GeneAmp PGR Systems 
9600 Thermocycler (Applied Biosystems, Foster City, CA). 
6.6 Purification of Sequencing Products 
The sequencing products contain unincorporated nucleotides, dye terminators, 
primers, salts and thermostable polymerase. They must be removed to prevent 
unsatisfactory sequencing gel images. The sequencing product was purified by 
Sephadex G-50 resin (Amersham Biosciences, Piscataway, NJ). Nine grams of resin 
was dissolved in 100 ml distilled water for producing a gel solution. MicroSpin G-50 
Columns (Amersham Biosciences, Piscataway, NJ) were pre-packed with 800 fil 
Sephadex G-50 gel solution, followed by 5-minute of centrifugation at 6000 rpm. IX 
TE buffer was added to enlarge the samples' total volume to 20 |iL The samples were 
applied to the packed-column, centrifuged at 8000 rpm for 5 minutes. The 
sequencing products were collected in 1.5 ml microcentrifuge tubes, dried with a 
DNA Speed-Vac Concentrator (Savant Instruments Inc., Farmingdale, NY). The 
dried DNA was resuspended in 5 of loading buffer including EDTA (25 mM) in 
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Blue Dextran (50 mg/ml; Applied Biosystems, Foster City, CA) and formamide 
(Sigma, St. Louis, MO). Before loading the samples to the sequencing gel, they were 
denatured for 5 to 10 minutes at 95°C. 
6.7 Sequence Analysis by Automated Sequencer 
6.7.1 Preparation of Poly aery lamide Gel 
Firstly, 40% of 19:1 acrylamide stock solution was prepared. As acrylamide and 
bisacrylamide are poisons, neurotoxins, irritants and carcinogens, preparation work 
had to be performed in a fiime hood. Nineteen grams of crystalline acrylamide and 
one gram of bisacrylamide were used to prepare 100 ml of solution. The solution was 
stirred in room temperature until all crystals were dissolved. The mixture was then 
filtered through a 115-ml filter unit with 0.2-fim surfactant-free cellulose acetate 
(Nalgene, Rochester, NY) and was stored at 2-6°C. 
To prepare 25 ml of 4% acrylamide gel solution, 9 g of urea was dissolved in 12.5 ml 
deionized water and 2.5 ml of lOX Tris-Boric acid-EDTA (TBE) buffer. Then 2.5 ml 
of 40% acrylamide was added and the solution was filtered. Deionized water was 
added to make the final volume to 25 ml. 
One hundred and twenty-five microliters of 10% ammonium persulfate (APS) 
solution and 17.5 \i\ of TEMED were added with careful swirling without 
introducing air bubbles. These two components promote the polymerization of the 
gel. Then a 0.2-mm vertical slab gel was casted according to user's manual of ABI 
Prism 377 DNA sequencer (Applied Biosystems, Foster City, CA). 
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6.7.2 Sequence Analysis by Automated Sequencer 
The mitochondrial sequence was analyzed by ABI Prism 377 DNA sequencer 
(Applied Biosystems，Foster City, CA) with Sequence Analysis Version 3.0 Program. 
It automatically analyzes fluorescent-labeled DNA fragments with four different 
dyes by gel electrophoresis. After samples were loaded onto the system's vertical gel, 
it undergoes electrophoresis and DNA fragments were separated according to their 
differences in size. The fluorescent signal was detected by a laser beam, followed by 
analysis by computer. The output data was stored in various formats including 
electropherogram. 
6.7.3 Search for Sequence Variants, Polymorphisms and Somatic 
Mutations 
The analyzed sequence for each sequencing reaction sample was compared with the 
respective location of modified Cambridge mitochondrial sequence (Accession 
number: JO 1415) using Basic Local Alignment Search Tool (BLAST; National 
Center for Biotechnology Information: NCBI). Any nucleotide position different to 
the accession number JO 1415 in either tumor, non-tumor or donor tissue was 
classified as sequence variant. Those sequence variants found at a particular location 
in both tumor and matched normal mtDNA were classified as polymorphisms. They 
were compared with those recorded in the extensive mitochondrial databank: 
MITOMAP and literatures on mtDNA mutations. Those not found in this database or 
literatures were classified as new polymorphisms, whereas those found were 
classified as reported polymorphisms. If the DNA sequence in tumor mtDNA 
differed from the matched normal mtDNA, this was defined as a somatic mutation. 
These sites were confirmed by a second time of cycle sequencing reaction. 
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6.8 Other Studies on mtDNA Mutations 
6.8.1 Sequence Analysis in Buffy Coat 
Several layers are formed when clotted whole blood is centrifuged. The upper layer 
is a clear fluid called serum (Study of mtDNA in serum will be discussed in Section 
6.8.2). The lower layer is the blood cells and the intermediate layer containing white 
blood cells (including lymphocytes) is buffy coat. Blood samples were collected by 
the Department of Surgery, the Chinese University of Hong Kong. They were frozen 
at -70°C and thawed to room temperature before the experiment. DNA from 
lymphocytes was extracted in four of the ten patients (d04, d05, d07, dl4). 
About 100 III of buffy coat was applied using High Pure PCR Template Preparation 
Kit (Roche Molecular Biochemicals, Mannheim, Germany). After incubating the 
buffy coat with 200 |LI1 binding buffer, each reaction mixture was pipetted to High 
Pure filter tube with the collection tube and centrifuged at 8000 rpm for 1 min. The 
flow-through was discarded followed by combining the filter tube with a new 
collection tube. Five hundred \x\ wash buffer was added to the upper reservoir. 
Centrifugation of the combined column was carried out at 8000 rpm for 1 min. The 
washing step was repeated followed by a full-speed centrifugation of the column for 
30 seconds. Finally the flow-through was discarded and the filter tube was combined 
to a new 1.5 ml eppendorf. DNA was eluted with 50 |j.l elution buffer. The reagents 
and protocols for PCR and sequencing reaction were similar as mentioned above. 
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6.8.2 Detection of the Presence of Somatic mtDNA Mutations in Plasma 
Circulating DNA from those cases with somatic mutation except case d06 was 
extracted from 400|il plasma using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, 
Germany) according to manufacturer's protocol. In brief, the serum samples were 
lysed by buffer AL, followed by incubation at 56®C and precipitation with absolute 
ethanol. The mixture was transferred to the spin column and the DNA would bind 
onto the resin. After two washing steps, the serum DNA was eluted. The continued 
steps for amplification of mtDNA and sequencing analysis were similar to Sections 
6.3 to 6.7. 
6.8.3 Frequency of Mutations in Two Nucleotide Repeat Sequences 
The sequence of two mutation sites was further investigated with more HCC cases. 
One of the site is a mononucleotide repeat region: poly-cytosine (C)n tract from 
nucleotide positions 303-315 (D310 in short). The other is a dinucleotide repeat 
sequence: (CA)n repeats from nucleotide positions 514-525. 
The paired tumor and non-tumor tissues in 50 HCC patients (including the ten 
patients in the entire genome analysis) from the year 1993 to 2001 were included in 
this experiment (coding: dOl to d60, clinical data is provided in Table 6.1 and 
Section 6.9). Most of the patients had chronic hepatitis B infection except for three 
of the cases (cases d40，d45 and d51) were not infected with HBV and one (case d26) 
had chronic HCV infection. Methods for extracting DNA were the same as that in the 
analysis of entire mitochondrial genome. The primers for amplifying the mtDNA 
region with the two microsatellite instability sites and sequencing reaction were 
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MTDLPC for forward and MT12SD for reverse (sequence of these two primers were 
presented in Table 6.2). The conditions and procedures of PCR, sequencing reaction 
and sequence analysis were mentioned in Sections 6.3 to 6.7. 
6.9 Clinical Data and Statistical Analysis 
6.9.1 Clinical and Pathological Data 
The clinical and pathological data of the 50 HCC patients were presented in Table 
6.1. Among them, forty were males and ten were females (male: female ratio = 4:1). 
The age of patients ranged from 17 to 75 years with a median of 56.5 years. Thirty-
three patients had died before the day of clinical data collection (February 2002). 
Twenty-five patients did not have a recurrence of HCC (including those patients died 
without a recurrence), and the other 25 had confirmed or suspected to have 
recurrences of HCC. Survival was calculated from the date of surgical resection to 
the last follow-up date if the patient is alive or to the date of death if the patient has 
died. Survival of these 50 cases ranged from 3 to 2613 days (85.9 months), with a 
median of 402 days (13.2 months). Day of recurrence was calculated from the date of 
surgical resection to the date of recurrence found or to the date of death if the patient 
has died. The median of day of recurrence was 254 days (8.4 months). 
Twenty-eight cases had cirrhosis confirmed by histopathology. The size of the 
tumors were divided into three groups: small (S): < 3.0 cm; medium (M): 3.1-6.0 cm; 
and large (L): > 6.1 cm respectively. For the stages of differentiation, 36 patients 
were classified as moderately differentiated, 3 were classified as poor and 10 were 
classified as well differentiated. 
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6.9.2 Statistical Analysis 
Statistical Package for Social Science software (SPSS) Version 10.0 (SPSS, Inc.) 
was applied for the following statistical analysis: 
a. Mann-Whitney test was performed to compare the number of sequence variants 
found for the whole mitochondrial genome analysis in the ten pairs of tumor/non-
tumor cases and that of the two normal livers. 
b. Chi-square test and Fisher's exact test were applied to find the correlation 
between the presence of somatic mutations at mononucleotide repeat sequence 
near 310 bp and clinical (sex, life status, presence or absence of recurrence) or 
pathological factors (size of tumor, stage of tumor cell differentiation, presence 
or absence of cirrhosis). A two-sided p-value of less than 0.05 was considered 
statistically significant. 
c. For the survival analysis, distributions of overall survival and disease-free 
survival in the presence of somatic mutations at mononucleotide repeat sequence 
near 310 bp were estimated by the Kaplan-Meier method, and comparisons were 
made with log-rank statistics. Results were considered significant for p values < 
0.05. A univariate analysis based on Cox proportional hazards regression model 
was performed to estimate whether the presence of somatic mutation is a 
prognostic factor. Three patients (d28, d38 and d45) were not included in 
survival analysis as they died shortly after surgery (post-surgical complications). 
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Section 7. Results 
7.1 Sequence Analysis of the Entire Mitochondrial Genome 
Figure 7.1 shows an agarose gel photo demonstrating the size distribution of the ten 
fragments amplified by PGR in case d04. As the ten large fragments representing the 
entire mitochondrial genome could be amplified by PGR, there were no major 
deletions or rearrangements of mtDNA in any sample. 
7.1.1 Sequence Variants and Polymorphisms 
By comparing the sequence in non-tumor tissues with that of the published 
Cambridge sequence, numerous germ-line sequence variants were found. Including 
the two donor controls, 182 sequence variants were found in the 10 pairs of HCC and 
non-tumor tissues. 126 were previously reported polymorphisms according to 
MITOMAP database and journal articles investigating mtDNA mutations in tumors, 
including 4 deletions and 1 insertion (for details of these articles, please refer to 
Section 4.6). 
Furthermore, 48 unknown polymorphisms were found. Twenty-six of them were 
silent changes within expressed sequences; eleven variants altered the amino acid 
sequence of the encoded protein, including six in NADH dehydrogenase genes 
(complex I), one from cytochrome c oxidase gene (complex IV) and four from ATP 
synthases (complex V). Five variants affected rRNAs sequence, three affected 
tRNAs, and two were in the non-coding region. The final one was a 1 -bp deletion at 
14413 bp, which provided a frameshift mutation in ND6 gene. A truncated protein 
with 69 amino acids was encoded, instead of 174 in the original protein. The loss of a 
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large portion of C-terminus portion in ND6 gene in tumor and non-tumor tissues may 
be an early event during progression of cirrhosis and HCC. 
Tables 7.1 and 7.2 give detail descriptions of the reported and new polymorphisms 
found in the ten HCC and the two control cases (including mutation sites, changes of 
nucleotide and amino acid sequences). Most of these mutations were T-to-C or G-to-
A base substitutions and implied that most of the mtDNA mutations may be caused 
by the high level of ROS, leading to base transition between pyrimidines and purines. 
More than half of the polymorphisms were found in more than one pair of cases, in 
which twenty-three of them occurred in more than half of the cases, which are 
frequent polymorphisms. 
Moreover, four mutations found in the two controls have not been reported as 
sequence polymorphisms. They were not classified as somatic mutations as the 
control specimens are normal liver tissue without liver disease or HBV infection and 
they could only be classified as new polymorphisms (Table 7.2). 
Fifty-three of the 182 sequence variants were found in the regulatory D-loop region. 
The reasons for the D-loop region to be a hypervariable region and mutation hotspot 
will be further discussed in Section 8.4. 
For the two controls, a large number of sequence variants (both were 36) were found, 
while the average number of variants found in the ten patients ranged from 26 to 53, 
with an average of 38.6. The Mann-Whitney test was performed to determine the 
correlation in the number of sequence variants between controls and patients, and no 
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significance was found between these two groups {p= 0.485). This is because 
mitochondrial DNA is highly polymorphic and is vulnerable to be damaged. 
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Figure 7.1 
An agarose gel photo showing size distributions of the ten large fragments in PCR 
amplification of the whole mitochondrial genome. The samples loaded were obtained 
from the tumor tissue of case d04. 
Lanes 1 & 12: Molecular size marker X Eco 1301, lane 2: Fragment 1 (871 bp), lane 3: 
Fragment 2 (2375 bp), lane 4: Fragment 3 (1522 bp), lane 5: Fragment 4 (2071 bp), 
lane 6: Fragment 5 (1893 bp), lane 7: Fragment 6 (1927 bp), lane 8: Fragment 7 (2608 
bp), lane 9: Fragment 8 (1907 bp), lane 10: Fragment 9 (948 bp)，lane 11: Fragment 
10 (1723 bp). 
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Gene Nucleotide Nucleotide 一 Codon Protein Case � 
Position J01415| Changed ‘ J01415 Changed Change Affected 
12S rRNA 709 G A N.A. N.A. N.A. dl5 
752 C T N.A. N.A. N.A. d07, d09 
1107 T C N.A. N.A. N.A. d07, d09 
1438 A G N.A. N.A. N.A. 18/22 
1 6 S rRNA 2 7 0 6 A G N . A . N . A . N . A . 2 2 / 2 2 
NDl 3423 T C GTT GTC Val to Val dl3 
3434 A G TAG TGC Tyr to Cys dl5 
3970 C T CTA TTA Leu to Leu d04, d05, dl5 
4048 G A GAC AAC Asp to Asn d06, dlOC 
4071 C T TAG TAT Tyr to Tyr d06, dlOC 
4086 C T GTC GTT Val to Val d05 
4164 A G ATA ATG Met to Met d06, dlOC 
tRNA-Gln 4386 T C N.A. N.A. N.A. dl2 
ND2 4715 A G G ^ ^ Gly to Gly d08 
4769 A G ATA ATG Met to Met 22/22 
4883 C T CCC CCT Pro to Pro d07, d09 
5108 T C ACT ACC Thr to Thr dl6C 
5178 C A CTA ATA Leu to Met d07, d09 
5231 G A CTG CTA Leu to Leu dl4 
5301 A G ATC GTC H e to Val d07, d09 
5351 A G CTA CTG Leu to Leu dO6, dlOC 
5417 G A CAG CAA Gin to Gin dl4 
5460 G A GCC ACC Ala to Thr d06  
COI 6179 G A ATG ATA Met to Met d08 
6392 T C AAT AAC Asn to Asn d05, dl5 
6455 C T TTC TTT Phe to Phe d06 
6680 T C ACT ACC Thr to Thr d06 
6962 G A CTG CTA Leu to Leu d05 
7028 C T GCC GCT Ala to Ala 22/22 
7196 C A CTC CTA Leu to Leu d08  
c o n 7684 T C OT ^ Leu to Leu dO6, dlOC 
7789 G A CTG CTA Leu to Leu dl6C 
7853 G A GTC ATC Val to lie dO6, dlOC 
8245 A G GAA GAG Glu to Glu d08 
8271-8279 Del 9bp N.A. N.A. N.A. dl3, dl6C 
ATP8 8426 T C TTC CTC Phe to Leu dO8 
ATP6 8584 G A ^ A ^ Ala to Thr d08 
8697 G A ATG ATA Met to Met dO7 
8701 A G ACC GCC Thr to Ala 10/22 
8860 A G ACA GCA Thr to Ala 22/22 
9053 G A AGC AAC Ser to Asn d05  
c o m 9180 A G GTA ^ Val to Val d07, d09 
9540 T C TTA CTA Leu to Leu 11/22 
9824 T C CTT CTC Leu to Leu dO6, dlOC 
N ^ 10310 G A CTG ^ Leu to Leu d05, dl5 
10397 A G TGA TGG Trp to Trp d07, d09 
10398 A G ACC GCT / GCC Thr to Ala 13/22 
(dl3) 
10400 C T ACC GCT Thr to Ala 11/22 
N ^ 10873 T C OT ^ Pro to Pro 11/22 
11065 A G CTA CTG Leu to Leu dl5 
11176 G A CAG CAA Gin to Gin d08 
11719 G A GGG GGA Gly to Gly 22/22 
11914 G A ACG ACA Thr to Thr dl2 
11944 T C CTT CTC Leu to Leu d07, d09 
12026 A G ATT GTT lie to Val dO7, d09 
ND5 12358 A G A ^ ^ Thr to Ala dl4 
12372 G A CTG CTA Leu to Leu dl4 
12405 C T CTC CTT Leu to Leu d06, dlOC 
12406 G A GTT ATT Val to lie dO5 
12705 C T ATC ATT lie to lie 13/22 
12717 T C ACC ACT Thr to Thr d05 
12811 T C TAG CAC Tyr to His d06, dlOC 
To be cont'd 
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13759 G A G^ K^K Ala to Thr d05 
1 4 1 1 0 T C TTC CTC Phe to Leu dl2  
ND6 14207 G A ACT ATT Thr to lie dl3 
14470 T C GGA GGG Gly to Gly d08  
CYB 14783 T C TTA CTA Leu to Leu 10/22 
15043 G A GGG GGA Gly to Gly 11/22 
15258 A G GAC GGC Asp to Gly dl4 
15301 G A TTG TTA Leu to Leu 11/22 
15326 A G ACA GCA Thr to Ala 22/22 
15487 A T CCA CCT Pro to Pro d08 
15670 T C CAT CAC His to His d05  
D-loop ^ G A N.A. N.A. N.A. d ^ 
54 G C N.A. N.A. N.A. d05 
73 A G N.A. N.A. N.A. 22/22 
150 C T N.A. N.A. N.A. 9/22 
152 T C N.A. N.A. N.A. dl2, dl4, dl6C 
199 T C N.A. N.A. N.A. d06, dlOC 
204 T C N.A. N.A. N.A. dlOC 
207 G A N.A. N.A. N.A. dl5 
225 G A N.A. N.A. N.A. dl2 
248 A Del A N.A. N.A. N.A. d05, dl5 
263 A G N.A. N.A. N.A. 22/22 
309 C C, CC, CCC N.A. N.A. N.A. 12/22 
or CCCC; 
Del C 
311 C INS C N.A. N.A. N.A. 21/22 (no 
d05T) 
316 A G N.A. N.A. N.A. dl2 
489 T C N.A. N.A. N.A. 11/22 
514,515 CA DEL CA N.A. N.A. N.A. 10/22 (No 
dl4N) 
16086 T C N.A. N.A. N.A. dl2 
16092 T C N.A. N.A. N.A. d07 
16093 T C N.A. N.A. N.A. dl5 
16104 C T N.A. N.A. N.A. dl2 
16111 C T N.A. N.A. N.A. dl4 
16129 G A N.A. N.A. N.A. d05N, d06, 
dl2, dl4 
16145 G A N.A. N.A. N.A. d04 
16171 A G N.A. N.A. N.A. dl4 
16172 T C N.A. N.A. N.A. d05 
16182 A C N.A. N.A. N.A. d07, d09, dl3, 
dl6C 
16183 A C N.A. N.A. N.A. d07, d09, dl3, 
dl6C 
16184 C T N.A. N.A. N.A. d08 
16189 T C N.A. N.A. N.A. 9/22 
16192 C T N.A. N.A. N.A. d04, d06 
16209 T C N.A. N.A. N.A. dl2 
16217 T C N.A. N.A. N.A. dl3 
16223 C T N.A. N.A. N.A. 13/22 
16240 A G N.A. N.A. N.A, dl3 
16243 T C N.A. N.A. N.A. d04 
16257 C A N.A. N.A. N.A. dl4 
16260 C T N.A. N.A. N.A. dl5 
16261 C T N.A. N.A. N.A. dl3, dl4 
16272 A G N.A. N.A. N.A. dl2N 
16293 A G N.A. N.A. N.A. d07, dl6C 
16297 T C N.A. N.A. N.A. d06, dlOC 
16298 T C N.A. N.A. N.A. d08, dl4, dl5 
16304 T C N.A. N.A. N.A. d04, d05 
16309 A G N.A. N.A. N.A. d04 
16319 G A N.A. N.A. N.A. d08 
16325 T C N.A. N.A. N.A. d08 
16327 C T N.A. N.A. N.A. dlOC 
16355 C T N.A. N.A. N.A. dl5 
16362 T C N.A. N.A. N.A. d07, d09, dl5 
16390 G A N.A. N.A. N.A. ^  
To be cont'd 
-68 -
16470 G A N.A. N.A. N.A. d ^ 
16471 G A N.A. N.A. N.A. d08 
16473 G A N.A. N.A. N.A. d08 
16519 T C N.A. N.A. N.A. 9/22 
Table 7.1 
Information on the 126 reported polymorphisms from ten HCC samples and two 
controls (cases dlOC and dl6C). 
The changes in nucleotide, codon and protein sequences are indicated where necessary. 
Those mutations which change the respective protein sequences are highlighted. The 
full names of protein can be found in the translation table of mtDNA (Table 2.2). If a 
certain mutation site was found in five or more HCC cases, the information on which 
cases affected are not provided. 
Abbreviation: N.A.: Changes of codon and protein sequence are not applicable. 
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12S rRNA 1393 G A N.A. N.A. N.A. dl3 
1541 T C N.A. N.A. N.A. ^  
16S rRNA2404 T C N.A. N.A. N.A. d ^ 
2835 C T N.A. N.A. N.A. d08 
3200 T C N.A. N.A. N.A. d ^  
3528 C T ^ G ^ Ala to Ala d07 
3531 G A CCG CCA Pro to Pro dl4 
3714 A G GTA GTG Val to Val dl2 
3834 G A ^ CTA Leu to Leu dl2  
tRNA-Gln4385 A T N.A. N.A. N.A. dl2 
t R N A - M e t 4 4 8 4 C A N . A . N . A . N . A . ^  
ND2 4772 T C GCT GCC Ala to Ala dl2 — 
Noncodl 5585 G A N.A. N.A. N.A. dl5 — 
Noncod2 5894 A G N.A. N.A. N.A. dl5 
COI 5913 G A GAC AAC Asp to Asn dl5 
5978 A G TGA TGG Trp to Trp d05, dl5 
7433 C T Tyr to Tyr dl2  
c o n 8110 T C ATT ATC H e to H e d06 
ATP8 8457 C T ACA ATA Thr to Met d09 
8508 A G A ^ A ^ Asn to Ser d07  
ATP6 8684 C T A ^ ATC The to H e d08 
8718 A G AAA. AAG Lys to Lys d05 
8853 A G TGA TGG Trp to Trp dl2 
8901 A G CTA CTG Leu to Leu dO9 
9127 A G P ^ ^ H e to Val dl2  
c o m 9512 C T TAG TAT Tyr to Tyr dl2 
9854 T C ACT ACC Thr to Thr dl5 
9968 C T G ^ OT Val to Val dl6C  
ND3 10274 T C CTT C ^ Leu to Leu dl2 
10320 G A ^ ^ Val to H e dl5  
ND4L 10736 C T TAG TAT Tyr to Tyr d04 
ND5 12354 T C ACT A ^ Thr to Thr dl2 
12714 T C ATT ATC lie to lie d04 
12882 C T TTC TTT Phe to Phe d05 
12923 G T TGA TTA Trp to Leu dO9 
13044 C T GCC GCT Ala to Ala d05 
13145 G A AGC AAC Ser to Asn dlOC 
13928 G C AGC ACC Ser to Thr d04, d05 
14097 C T ； ™ T M Tyr to Tyr dl2  
N ^ 14259 G A CCT TCT Pro to Ser dl6C 
14413 C Del C Truncated Protein from the d09 
codon after the mutation site 
14429 C A TGG TTG Trp to Leu dO5, d06 
era 14971 T C TAT T ^ Tyr to Tyr dl5 
14974 C T GGC GGT Gly to Gly dl2 
15229 T C GTT GTC Val to Val dl2 
15565 T C TAT TAG Tyr to Tyr d05 
15691 A G ATA ATC Met to Met dl2  
tRNA-Pro 15973 A G~~ N.A. d l ^ 
Table 12 
Information on the 48 new polymorphisms from ten pairs of tumor and non-tumor 
tissues and two donor controls. 
The changes in nucleotide, codon and protein sequences are indicated where 
necessary. Those mutations which change the respective protein sequence are 
highlighted. Noncodl is the noncoding sequence between tRNA-Trp and tRNA-Ala， 
noncod2 is the noncoding sequence between tRNA-Tyr and COI. 
N.A.: Changes of codon and protein sequences are not applicable. 
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7.1.2 Somatic Mutations 
In the ten pairs of HCC and non-tumor tissues used for whole genome analysis, 
twelve somatic mutations were found. These mutations were presented in 70% (7 in 
10) of HCC. Figures 7.2 A to L are the electrophreograms showing the presence of 
these mutations. The information of these mutations, the comparison of the 
nucleotide sequences between tumor, adjacent non-tumor tissues and lymphocytes 
from the patients are also provided. Multiple mutations occurred in 4 of the 7 cases 
(d05, d07, dl4, dl5), including three somatic mutations found in one HCC patient 
and two somatic mutations in three patients. This implies possible accumulations of 
mtDNA damage by ROS in multiple sites. 
Both D-loop and ND5 gene were defined as mutation hotspot regions, with five (42%) 
and four (33%) somatic mutations found in this study. Two somatic mutations 
changed the sequence in tRNA-Met and tRNA-Phe. The last one was presented in 
the overlapping reading frame between and^TP^ gene. 
Eight of the twelve somatic mutations were at homoplasmic state in tumor tissue, 
such that the mutation was apparently present in every mitochondrial genome. The 
other four were heteroplasmic mutations (nucleotides 4408，8545, 13289 and 13367)， 
which suggested the wild-type and mutated sequences were mixed together. From 
the electrophreogram on Figure 7.2, about 70% of mutated sequences were present 
in the tumor tissues. 
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A Electrophreograms on sequence analysis using forward primer MTDLPF 
Patient I Nucleotide I Gene Nucleotide Changed Codon Changed Protein 
Position J01415 Tumor Non- BufTy N o n - T u m o r Changed  
tumor coat tumor  
d15— 60 D-Loop T | C 丨 T | N.D. N.A. N A N.A. 
Jr V  
G T A T T T C C G T C "： G T A T T T T C G T C 
390 390 ‘ 
Tumor Non-tumor 
B Electrophreograms on sequence analysis using forward primer MTDLPC 
Patient Nucleotide Gene Nucleotide Changed Codon Changed Protein~ 
Position J0141S Tumor Non: BufFy N o n - T u m o r Changed  
tumor coat tumor  
Cio, Cii CsTCs, CsTCs, 
d05 303-315 D-Loop C7TC5 (Del 5/ C9TC5, C9TC5, N.A. N.A. N.A.  
6-bp) C10TC5 C10TC5  
A C C C C C C C C C C C G C N T T N G G � C. c C C C C C C N T C C C C C C G C C T ” G G 
250 260 230 240 250 
A A 
Tumor Non-tumor 




To be cont'd 
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C Electrophreograms on sequence analysis using forward primer MTDLPC 
Patient I Nucleotide I Gene Nucleotide Changed Codon C|ianged Protein 
Position J01415 Tumor Non- Buffy N o n - T u m o r Changed  
tumor coat tumor  
d14 514-525 D-Loop (CA)5 (CA)4 (CA)5 (CA)5 N.A. N.A. N.A. 
A G C A C A C A C A C C A G C A C A C A C A C A C C A G C A C A C A C A C A C C ' 
440 :40 450 450 
( w m ( w m i b e ^ ( w M Y ^ v 
Tumor Non-tumor Buffy Coat 
D Electrophreograms on sequence analysis using forward primer MTDLPE 
Patient I Nucleotide j Gene Nucleotide Chang叫 Codon C^ianged Protein“ 
Position J01415 Tumor Non: Buffy Non-~Tumor Changed  
tumor Coat tumor  
d06 605 T C T N.D. N.A. N.A. N.A. Phe [ _ _ 
I I 
A A A G C A A C A C A C T A A A G C A A T A C A C I 
280 300 
Tumor Non-tumor 
To be cont'd 
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E Electrophreograms on sequence analysis using reverse primer MTNAD1C 
Patient I Nucleotkle I Gene I Nucleotide Change^ | Codon C ” a n g ^ P r o t e i n ~ 
Position J01415 Tumor Non- Buffy N o n - T u m o r Changed  
tumor coat tumor  
(107 4408 G A+G G G N.A. N.A. N.A. Met  
\ I I 
T T T A G C T G A T C T T A T T T A G C T G A C C T T A ( K T T T A G C T G A C C T T A 
120 13 120 130 0 130 
kUMuM^HMk 
Tumor Non-tumor Buffy Coat 
F Electrophreograms on sequence analysis using forward primer MTATP8A 
Patient Nucleotide G e n e N u c l e o t i d e Changed Codon fhanged Protein 
Position J01415| Tumor Non- Buffy N o n - T u m o r Changed  
tumor coat tumor  
ATPaseS: ATPaseS: ATPaseS: 
…7 oi^ R ATPase 8 广 “ r r r TC(3 TCA Ser->Ser 
d07 8545 ATPase 6 G A+G G G ATPase6: ATPase6: ATPase6: 
I I I I |GCT |ACT Ala~»Thr 
i i i  
C T G T T C A C T T C A : T G T T C G C T T C A � ' C T G T T C G C T T C A 
420 430 4< 0 440 
^ v / W M jArnhh W ) ( V W \ / 
Tumor Non-tumor Buffy Coat 
To be cont'd 
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G Electrophreograms on sequence analysis using reverse primer MTNAD5A 
Patient Nucleotide Gene Nucleotide Changed Codon Changed Protein 
Position J01415 Tumor Non- Buffy N o n - T u m o r Changed  
tumor coat tumor  
d04 12389 I ND5 I C I T | C | C | CCC CCT Pro-)>L^ 
_ jt >|r i  
� G — g I t — g a g g g g a a a g g a t g g g g g g a a a A … … G … T � 
210 220 220 230 
r j ^ ^ m ^ ^ 
Tumor Non-tumor Buffy Coat 
H Electrophreograms on sequence analysis using reverse primer MTNAD5A 
Patient I Nucleotide I Gene Nucleotide C h a _ ” Codon C|ianged Protein“ 
Position J01415 Tumor Non~ Buffy N o n - T u m o r Changed  
tumor coat tumor  
d15 ~ 12519 ND5 T | C | T | N.D. GTT GTC Val-»Val 
I I 
C G AG ATA AT GA C T T ' C G A G A T A A T A A C T T 
100 110 100 110 
mmm 
Tumor Non-tumor 
To be cont'd 
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I Electrophreograms on sequence analysis using reverse primer MTNAD5C 
Patient Nucleotide Gene Nucleotide Changed Codon Changed Protein 
Position J01415 Tumor Non- Buffy N o n - T u m o r Changed  
tumor coat tumor  
d05 13289 ND5 G A+G | G 丨 G 丨 GGC GAC Gly~»As"^ 
X Jr V  
T T G A T G T C G A T T T T G A T G C C G A T T J T T G A T G C C G A T T 
120 13( 150 140 150 
i M ^ wMi^ w t f W v 
Tumor Non-tumor Buffy Coat 
J Electrophreograms on sequence analysis using reverse primer MTNAD5C 
Patient Nucleotide Gene Nucleotide Changed Codon Changed Protein 
Position J01415 Tumor Non: Buffy N o n - T u m o r Changed  
tumor coat tumor  
d14 13367 ND5 G A+G | G | G | GGG GAG Gly~>diir~ 
_ i i ^ _ _ . 
T G G A C T C G G A G C A T G A T G G A C C C G G A G . T G A T G G A C C C G G A G ( 
50 70 50 
Tumor Non-tumor Buffy Coat 
To be cont'd 
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K Electrophreograms on sequence analysis using reverse primer MTDLPD 
Patient Nucleotide Gene Nucleotide Changed Codon Changed Protein 
Position J01415 Tumor Non: Buffy N o n - T u m o r Changed  
tumor coat tumor  
d05 16129 I d-LOOP I G I G I A | A | N.A. N.A. N . A . — 
i I i  
G G T A C C G T A G G T A C T G T A C a T G G^T A c t G ta c A A^ ' 
290 2 9 0 
j^WvWW / w w y ^ 
Tumor Non-tumor Buffy Coat 
L Electrophreograms on sequence analysis using reverse primer MTDLPD 
Patient I Nucleotide I Gene Nucleotide Changed Codon Changed Protein 
Position J01415 Tumor Non: Buffy N o n - T u m o r Changed  
tumor coat tumor  
d12 16272 D-Loop A | A | G | N.D. N.A. N.A. N.A. 
i _ I 
G G T A C C G T A G G T A C T G T A C 
290 2 9 0 
Tumor Non-tumor 
Figure 7.2 A to L 
Electrophreograms show information on the 12 somatic mutations found in the ten 
HCC cases, including the gene involved, the position of nucleotide(s), the 
comparison of nucleotide changes in tumor, non-tumor and buffy coat DNA with 
Cambridge mitochondrial sequence: J01415. For the mutations in coding genes, the 
changes in codon and protein are also included. 
The arrows on top of each nucleotide position indicate the actual nucleotide position, 
excluding the two nucleotide repeat sites where no arrow is indicated (More 
information is provided in Sections 8.5 and 8,6). 
Nucleotides 4408，8545, 13289 and 13367 were heteroplasmic mutations, where both 
normal and mutated sequences were recorded. 
Abbreviations: N.A.: the changes in codon and protein are not applicable，N.D.: the 
sequence analysis was not done in buffy coat. -77 -
7.2 Study of Mitochondrial Sequence in Lymphocytes 
Eight of the twelve somatic mutations were included (nucleotides 303-315, 514-525, 
4408，8545，12389，13289, 13367 and 16129) in the four cases with their 
lymphocytes DNA analyzed (cases d05, d07, dl4 and dl5). The sequences of these 
mutation sites in lymphocytes were matched with that in their respective non-tumor 
tissues, i.e., the somatic mutations in tumor tissue were not found in their matched 
lymphocytes. As buffy coat contains DNA from lymphocytes, it is suggested that the 
DNA sequence is normal. This indicated that the mutated sequence found in tumor 
tissues were truly somatic. 
7.3 Detection of Tumor DNA in Serum 
The serum sample from case d06 cannot be collected, so eleven of the twelve 
somatic mutation sites had been analyzed from six cases (multiple mutations were 
present in some cases). However, the sequence analyzed only matched with those 
found in normal (results not shown). This is because the tumor DNA in serum is so 
diluted with normal DNA (about 1:200 to 1:500) (Tan et al” 2002). Therefore, they 
cannot be detected by traditional PCR amplification and cycle sequencing reaction. 
In other reports, these circulating tumor DNA can be detected by methods like 
oligonucleotide mismatch ligation assay (Fliss et al., 2000; Hibi et al., 2001b; 
Jeronimo et al.’ 2001; Nomoto et al.，2002). 
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7.4 Analysis of Nucleotide Repeat Sequences 
7.4.1 General Results 
This study has examined the sequence in 50 pairs of HCC cases in two nucleotide 
repeat sites. The number of repeated sequences found in these two sites is given in 
Table 7.3. 
For the mononucleotide poly-C tract repeat sequences, 13 somatic mutations were 
found (including the one in entire genome analysis). This encompassed 26% of the 
total cases investigated. Seven mutations were heteroplasmic in either tumor or non-
tumor tissue with a mixed population of sequences. Two were at heteroplasmic state 
in normal tissue, four were at heteroplasmic state in tumor tissue and one was at 
heteroplasmic state in both tissues. 
Eleven of these somatic mutations were present as 6 to 9 Cs in the first stretch of 310 
bp. However, two cases had different results which are shown on Figure 7.3. In case 
d05, the non-tumor tissue contained a mixture of 8 to lOCs in the first stretch of 
poly-C, followed by 5 cytosine residues after the thymine at 310 bp. A continuous C-
tract with a mixed population of lOCs and l lCs was observed in the tumor tissue. 
The thymine at 310 bp and the nearby four to five Cs were deleted. Therefore, a total 
of 5- or 6-bp was deleted in the tumor sample. In another patient (d35), there was a 
9-bp deletion from 314 to 322 bp in tumor, but not in the corresponding non-tumor 
tissue. This would delete the replication primer sequence at 317 to 321 bp, and may 
alter the replication process. 
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There were six cytosine residues in the second stretch of poly-C in all cases 
examined except tumor tissue of d35, instead of five in the Cambridge sequence. It is 
presented as a polymorphism in the MITOMAP database. This polymorphism was 
also presented in a previous study of 59 HCC cases (Nishikawa et al, 2001). 
However, the examination of dinucleotide CA repeats gave different results. The 
number of CA repeats were 4 (40%), 5 (56%) and 6 (2%) respectively, but somatic 
mutation was found in only one case: from (CA)5 in non-tumor to (CA)4 in tumor in 
dl4 (electrophreogram shown in Figure 7.2C). The mutation frequency was only 2% 
in these 50 cases. 
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FPatientl T/N I D310L(C)n i P310R(C>n I Pinucl#otld#(CAIfl I 
hm “ T ” 8 6 4 
N 8 6 4 
f 8 6 5 
d02 N 8 /9 6 5 
T 7 6 5 
d03 ^ 7 6 5 
T 7 6 4 
d04 N 7 6 4 
~ ^ T Continuous 10/11 C, delete 516-bp 4 
N 8 / 9 / 1 0 6 4 
""；；： f 8 6 5 
d06 N 8 6 5 
f 7 6 4 
N 7 6 4 
f 7 6 5 
d08 N 7 6 5 
^ 0 9 ； I ？ ^ 
f 8 6 4 
d12 N 8 6 4 
"；；：；： f 6 6 5 
d13 N 6 6 5 
T 7 6 4 
d14 ; 7 6 5 
nil； T 8 6 5 
N 8 6 5 
T 7 6 5 
d21 N 8 6 5 
"；；;: T ^ 6 4 
似 N 6 4 
T 7 6 4 
d23 N 7 6 4 
""；；: f 8 6 5 
N 8 6 5 
""；；;: T 7 6 4 
N 7 6 4 
" Z Z f 8 6 5 
d26 N 8 6 5 
; � � 55 — 
d28 ；; T • 置 一 
d29 I I I I 
T 8 6 4 
謂 N 8 6 4 
T ^ 6 5 
N 819 6 5 
f 8 6 5 
d34 N 8 6 5 
~ ^ t 8 Delete 9-bp from np 314 5 
N 8 6 5 
T ~ 8 6 4 
d36 N 8 6 4 
T 7 6 5 
d37 N 7 6 5 
To be cont'd 
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II 3^8 I I I I 1 
I I I I 
d40 i； ( � ： 
T BT9 6 6 
N 8 6 6 
f 8 6 5 
d42 N 8 6 5 
r \ \ \ 
N 7 6 4 
T 7 6 5 州 N 7 6 5 
- 7 6 4 
•45 M 7 c A 
N 7 6 4 
t 7 6 4 
d46 N 8 6 4 
h.7 T 8 6 4 
°辟' N 8 / 9 / 1 0 6 4 
d48 \ \ \ ~~ 
I I I I ~~ 
d50 i； T • • 一 
… T 7 / 8 6 4 
棚 N 8 6 4 
T 6 / 7 6 5 啦 N 7 6 5 
Hc. T 7 6 4 
054 M 7 C 
N 7 6 4 
H « t 7 6 4 
055 "7 c A 
N 7 6 4 
~ d 5 6 I \ I I 
N 7 6 4 
狀 7 f 7 6 5 
d57 N 7 6 5 
d58 g • ： 一 
咖 ： T • 雪 一 
rifin T 8 / 9 6 5 
N 8 / 9 6 5 
Table 7.3 
Analyses of two nucleotide repeat sequences from 50 HCC cases, including a 
mononucleotide repeat from 303 to 315 bp and a dinucleotide CA repeat from 514 to 
523 bp. The former is divided into the C-tract before 310 bp (D310L) and from 311 
bp onwards (D310R). 
Numbers indicated in each row are the number of cytosine residues (C)n or CA 
repeats (CA)n. Ten of these cases were also included in the study of the whole 
mitochondrial genome (d04 to dl5). Columns highlighted in yellow indicate the 
presence of somatic mutation at D310 and the column highlighted in blue indicates 
the presence of somatic mutation at 514 bp. 
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eased05 5 or 6-bp including Tat 310 
bp was deleted in tumor 
A C C C C C C C C N T C C C C C C G C C T T T G G 
230 240 250 
— I M A A A A A — A A M M ^ ^ 
A C C C C C C C C C C C G C N T T N G G 
250 260 
— — 
Tumor a a 
Case d35 A 9-bp deletion in tumor 
from 314 to 322 bp 
+ y 
A A A C C C C C C C C T C C C C C C G C T T C T G G C C 
240 250 260 
Non-tumor A A A 
9-bp deleted 
A A A C C C C C C C N T C C C G G C C . 
p 240 250 
Tumor 
Figure 7.3 
The two obvious deletions (one was 5- or 6-bp and one was 9-bp) observed in the 
mononucleotide repeat sequence near 310 bp. 
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7.4.2 Statistical Analysis 
For the fifty patients with the mononucleotide repeat sequence D310 analyzed, no 
correlation was found between the presence of somatic mutation in poly-cytosine 
(C)n tract at 310 bp and the clinical and pathological information (including sex, 
tumor sizes, stage of differentiation, presence of cirrhosis, presence of recurrence, 
life status) by Pearson's Chi-square test and Fisher's exact test (data not shown). 
Figure 7.4 shows the overall and disease-free survival curves of HCC patients based 
on the presence of somatic mutations at D310 by Kaplan-Meier analysis and log-rank 
test. For the overall survival statistics, the median survival was 293 days (9.7 months) 
for patients with somatic mutations at D310 and 808 days (26.9 months) for patients 
without mutations. For the disease-free survival, the median survival was 144 days 
(4.8 months) for mutation-positive patients compared with 374 days (12.5 months) 
for mutation-negative patients. Therefore, there were significant correlations between 
this molecular abnormality and both overall survival and disease-free survival (p= 
0.0324 andp= 0.0179，respectively by log-rank test). 
Figure 7.5 shows the overall and disease-free survival curves based on the largest 
diameter of tumor (size of tumor) by Kaplan-Meier analysis. There were significant 
correlations with both overall (p= 0.0118 for log-rank test) and disease-free survival 
(p= 0.0134) respectively. 
The results of Cox univariate proportional hazard regression analyses are given in 
Table 7.4. It showed that the presence of mutation at D310 (p= 0.038) and largest 
diameter of tumor (p= 0.007) were the significant indicators in overall survival. In 
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fact, these two factors were also significant indicators in disease-free survival (p= 
0.022 for mutation at D310 andp= 0.005 for tumor size). 
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A Mutation at D310 on Overall Survival 
12 p= 0.038 
- 1 . 1 
(0 ^ 
I .8, \ 
CO \ 
I .6, L ^ 
ro L|, Absence (^ n= 36) 
2 1 ’ 1 1 ^ 
Presence (n= 11) 
n n | _ _ _ . . . , 
0 300 600 900 1200 1500 1800 2100 2400 2700 
Survival after resection (days) 
B 




.1 .6. L \ 
ro h I 
3 Vh 1 Absence (n= 36) 
3 “ I 
H h 
.2 I 
• Presence (n= 11) ^ 
0� ]——.——.——.——.——.——.——.——.——_ 
0 300 600 900 1200 1500 1800 2100 2400 2700 
Recurrence after resection (days) 
Figure 7.4 
Survival curves of Kaplan-Meier analysis for overall survival (A) and disease-free 
survival (B) according to the presence of somatic mutation in mononucleotide 
repeats near 310 bp in patients with HCC. 
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A 
Tumor Size on Overall Survival 
1.21 
p= 0.007 
1 • � 
75 ^H-v 
•I -S- L 
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§ I 
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3 .41 
Large (n= 14) + 
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Section 8. Discussion 
8.1 Comparative Analysis of mtDNA Mutations with Two 
Previous HCC Studies 
Excluding this study, there were only two previous reports on somatic mtDNA 
mutations in HCC. A comparative analysis of these studies will be discussed. 
8.1.1 Number of Cases and Region Studied 
This study has the advantages over the other two in two areas: 
(1) The number of cases studied: This study investigated the presence of somatic 
mutations in ten HCC cases for the entire genome, while Nishikawa et al. 
only studied two cases (Nishikawa et al., 2001). 
(2) The length of mtDNA studied: This study analyzed the entire mitochondrial 
genome, while Nomoto et al. searched for mutations in the D-loop region 
only (Nomoto et al., 2002). 
In this study, the aberrations at two nucleotide repeat sequences in the D-loop (303-
315 and 514-525 bp) from 50 samples were determined, while Nishikawa et al, 
performed mutational sequence analysis in part of the D-loop region (100 to 600 bp) 
in 59 cases of HCC. 
8.1.2 Number and Distribution of Mutations in Normal Controls 
A significant difference between Nishikawa et al. and this study were found in terms 
of the number and distribution of mutation sites in the control liver specimens. In this 
study, the average number of mutation sites found in the two normal specimens were 
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36, and they were distributed over the entire genome. However, Nishikawa et al 
reported only three mutation sites in one control liver sample and these mutation sites 
were confined in the D-loop region. It is believed that mtDNA has a high mutation 
rate due to the presence of ROS and so many polymorphisms and germ-line 
mutations can be found even in normal tissues when compared with the Cambridge 
reference sequence (Stoneking, 2000; Kirches et al., 2001). Although the control 
liver sample in Nishikawa's group had other liver diseases (hepatolithiasis or 
colorectal carcinoma with liver metastasis), it was unlikely that this would greatly 
reduce the number of sequence variants. 
8.1.3 Number of Somatic Mutations 
A great contradiction was also observed between the result of Nishikawa et al and 
this study in terms of the number of somatic mutation sites. In this study, the number 
of somatic mutations found in each tumor case was much lower (0 to 3), such that the 
number of sequence variants between tumor and non-tumor tissues was similar. 
Nishikawa et al reported approximately 75 mutation sites were found in each tumor. 
This finding was substantially higher than that reported in other tumor types. 
Furthermore, about 40 mutation sites were found in each non-tumor tissue. By 
comparing the sequence between tumor and non-tumor tissues, about 35 to 40 
somatic mutations were found in each case. However, compared with control liver 
tissue, the frequency of mtDNA mutations was markedly increased in both 
noncancerous and cancerous liver specimens. Nishikawa et al suggested that the 
hepatocytes might have already undergone the initial stage of malignant 
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transformation in chronic inflammation induced by virus infection, followed by rapid 
replication of mitochondria and accumulated DNA damages (Nishikawa et al,, 2001). 
Our results concurred with the general profile of other somatic mutation studies, in 
which a few somatic mutation sites were found in most cases affected. Nevertheless, 
large number of mutations had been found in two other studies. In a study of prostate 
cancer, 18 somatic mutations were found in one tumor (Jeronimo et al., 2001). 
Jeronimo et al. suggested that these multiple mutations might be the result of a 
limited but catastrophic mutagenic effect from an excessive exogenous exposure in a 
chemical plant (Croteau et al., 1997). In another study of glioblastoma by Kirches et 
al., they reported 17 homoplasmic mutations in a single tumor sample and explained 
that fast clonal selection in certain tumor mitochondria leading to a large number of 
mutations (Kirches et al., 2001). 
To conclude, the intriguing number of mutations reported by Nishikawa et al. may 
not be representative. This may not be the general mutation profile in HCC and could 
not be explained by their suggestions that most mutations were caused by initial 
hepatitis viral infection. 
8.1.4 Distribution of Somatic Mutations 
The percentage of mutations in the D-loop region in this study was higher than 
Nishikawa,s study (42% versus 14%) because of the intriguing large number of 
somatic mutations found in the coding gene in the latter study. Furthermore, this 
finding cannot be compared with Nomoto’s study as they only studied the D-loop 
region. However, for the mutations in mononucleotide repeat sequence, 42% (8 of 19) 
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of multicentric HCC samples were mutated in Nomoto's study and 26% of HCC (13 
of 50) samples were mutated in ours. The smaller sample size may be the reason for 
a higher percentage in the former study. 
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8.2 Similarities of Somatic mtDNA Mutations in This Study 
with Other Cancer Types 
8.2.1 Frequency and Distribution of Somatic Mutations 
In our study, the frequency of somatic mutations was 70%. In other tumor studies 
analyzing more than 80% of mitochondrial genome, the frequency ranged from 43% 
to 100% (Table 4.1). The incidence of somatic mutation in our HCC cases was 
within this range, showing that somatic mutation was frequent in HCC. 
Most of the somatic mutations in our study were distributed in the D-loop (42%) and 
ND5 (33%) genes. The others were located at the two tRNAs and a junction between 
ATP8 and ATP6. As only 12 sites were found in this study, the general distribution of 
somatic mutations in HCC cannot be determined accurately. From Table 4.2, a large 
proportion of mutations were found in the non-coding D-loop region from previous 
studies and ours, while the distribution of mutation sites in other coding genes 
remains unclear. 
8.2.2 Number of Homoplasmic Mutations 
Coller et al. suggested calculating the number of homoplasmic mutations per tumor 
(Coller et al” 2001). Table 8.1 shows the calculation of homoplasmic mutations in 
studies analyzing more than 80% of mitochondrial genome. The number of 
homoplasmic mutations per tumor ranged from 0.5 to 1.21. The average number of 
mutations found in a total of 95 cases was 0.84. The number of homoplasmic 
mutation in this study (0.8) was close to the average, while an extraordinary high 
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value (40 per tumor) was obtained in another HCC study by Nishikawa et al 







































































































































































































































































































































































































































































































































































































































8.3 Evaluation of Somatic Mutations of mtDNA in This 
Study 
8.3.1 Specificity of Somatic Mutations in Tumor Proved by Sequence 
Analysis in Lymphocytes 
Eight of the twelve somatic mutations were included in the mtDNA sequence 
analysis in lymphocytes (Please refer to Figure 7.2 for details). As buffy coat 
contains DNA from lymphocytes, it is suggested that the DNA sequence is normal, 
except in individuals with blood-bome disease like leukemia. From the results, the 
sequence profile of white blood cell DNA was matched with that in non-tumor 
tissues. This means that the mutated sequence could be detected in HCC tissues of 
the patients, but not in their corresponding non-tumor liver tissues or buffy coat by 
automated sequencing. Therefore, the mutated sequences found in tumor tissues were 
truly somatic mutations. These somatic mutations found in the tumor samples may 
solely the cause or effect of genetic change during tumor initiation and progression. 
8.3.2 Importance of Conserved Amino Acid Sequences with Other 
Species to the Presence of Somatic Mutations in Tumor 
Four of the 12 somatic mutations found in this study showed changes in the amino 
acid sequence in coding genes. Three of these four missense mutations were present 
in the ND5 gene. In order to know the evolutionary conservation of ND5 gene, 
alignment of human ND5 gene with four other organisms was taken using ClustalW 
Program in European Molecular Biology Laboratory (EMBL; 
http://www2.ebi.ac.uk/clustalw/). Figure 8.1 shows the comparison of homologs of 
-96 -
ND5 gene in five organisms: Homo sapiens, Mus muscuius, Caenorhabditis elegans, 
Drosophila melanogaster and Artemia franciscana. In general, 12.3% (74) of the 
amino acid sequence in the four organisms was identical with human ND5 gene, 
while 21.9% (132) was conserved or semi-conserved substitutions with similar 
polarity. 
The G to A substitution at nucleotide position 13367，which is the 344th amino acid 
in ND5 gene, identical sequence (glycine) is found in all five organisms. This 
hydroxy amino acid was mutated to an acidic glutamic acid in patient dl4. 
Furthermore, it is shown that the conserved sequences of ND5 are mainly 
concentrated at three regions: codon 86-185, 216-263 and 278-397 from the N-
terminal. As this mutation is present in one of the conserved region, the change in 
polarity in amino acid sequence may affect the structure and function of ND5 protein. 
The G to A substitution at nucleotide position 13289, which is the SIS^ "" amino acid 
in ND5 gene, semi-conserved substitution is found in these organisms (In 
Caenorhabditis elegans, glycine was changed to serine). Similar change in polarity 
occurred, the hydroxy amino acid was mutated to an acidic aspartic acid in patient 
d05. The structure and function of ND5 protein may be affected due to the presence 
of this mutation site at the conserved region. 
The C to T transition at nucleotide position 12389, which is the amino acid in 
ND5 gene, has a change in amino acid sequence from proline to leucine, both are 
hydrophobic. However, this amino acid is at the N-terminal of protein and it is not 
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present in some organisms. Therefore, the change of this codon may be insignificant 
in the structure of protein. 
The last mutation in the coding region occurred in the overlapping region near the C-
terminal of ATP8 and the N-terminal of ATP6. The amino acid sequence for ATP8 
was unchanged but that of ATP6 was changed from hydrophobic alanine to hydroxy 
threonine. However, this alanine residue is only conserved in mammals but not in 
other species such as Drosophila melanogaster and Artemia franciscana (data not 
shown). Hence, insignificant effect on the structure and function of ATP 6 may occur 
in this case. 
ND5 gene is one of the subunits in complex I during OXOPHS process for accepting 
electrons from NADH. Three somatic mutations found in ND5 gene with a change in 
amino acid sequence mutations in conserved amino acid sequences may introduce 
structural and functional changes in human mitochondrial genes, and may be the 
causes or outcomes in tumor progression. 
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H. sap. 1 MTMHTTMTTLTLTSLIPPILTTLVNPNKKNSYPHYVKSIVASTFIISLFP 50 
M. mus. 1 MNIFTTSILLIFILLLSPILISMSNLIKHINFPLYTTTSIKFSFIISLLP 50 
C. ele. 1 MNISIFLIGFVFFMGGIS 18 
D. mel. 1 MCSISFVNLISMSLSCFL 18 
A. fra. 1 MCISLHLTVYRSNKCLLL 18 
H. sap. 51 TTMFMCLDQEVIISNWHWATTQTTQLSLSFKLDYFSMMFIPVALFVTWSI 100 
M. mus. 51 LLMFFHNNMEYMITTWHWVTMNSMELKMSFKTDFTSILPTSVALFVTWSI 100 
C. ele. 19 VWLMPTFKLGIFFLEWDFLSLK FNFYFNSILFSFILFLVTFSV 61 
D. mel. 19 LSLYFLLNDMIYFIEWELVSLNSMSIVMTFLFDWMSLLFMSFVLMISSLV 68 
A. fra. 19 IFIIPISWNLLIKNILFAFGLS SVLWLAKTIIHLLSSLNSSQV 61 
H. sap. 101 MEFSLWYMNSDPNINQFFKYLLIFLITMLILVTANNLFQLFIGWEGVGIM 150 
M. mus. 101 MQLSSWYMHSDPNINRFIKYLTLFLITMLILTSANNMFQLFIGWEGVGIM 150 
C. ele. 62 LVFSTYYLNSELNFNYYYFVLLIFVGSMFSLNFSNSIFTMLLSWDLLGIS 111 
D. mel. 69 IFYSKEYMMNDNHINRFIMLVLMFVLSMMLLIISPNLISILLGWDGLGLV 118 
A. fra. 62 MIYSSYYMMGETFVNRFMYMMLGFISSMVLLIMSSDGLSLMLGWDGLGIT 111 
• "k • • "A" • • "k • • • "k • • • • • "k • • "k • 
• • • • • 攀 • * * • • • 鲁 •鲁 
H. sap. 151 SFLLISWWYARADANTAAIQAILYNRIGDIGFILALAWFILHSNSWDPQQ 200 
M. mus. 151 SFLLIGWWYGRTDANTAALQAILYNRIGDIGFILAMVWFSLNMNSWELQQ 200 
C. ele. 112 SFFLVLFYNN-WDSCSGAMNTALTNRLGDYFMFVFFGLSVFSG-YYFLSF 159 
D. mel. 119 SYCLVIYFQN-IKSYNAGMLTALSNRIGDVALLLSIAWMLNYGSWNYIFY 167 
A. fra. 112 SYLLIMFYKN-YNSSSSGMITILSNRVGDVLILWSLGLMFYSKSWDYMFL 160 
'k * -k • • • • • • -k -k • -k -k • • • 
H. sap. 201 MALLNAN-PSLTPLLGLLLAAAGKSAQLGLHPWLPSAMEGPTPVSALLHS 24 9 
M. mus. 201 IMFSNNN-DNLIPLMGLLIAATGKSAQFGLHPWLPSAMEGPTPVSALLHS 24 9 
C. ele. 160 SMFSS YMSLLLLLTAFTKSAQFPFSSWLPKAMSAPTPVSSLVHS 203 
D. mel. 168 LEIMQNEFEMLMIGSLVMLAAMTKSAQIPFSSWLPAAMAAPTPVSALVHS 217 
A. fra. 161 SYFSL SIMLLFILSSFTKSAQLPFSAWLPAAMAAPTPVSSLVHS 204 
• . . • . . * * * -k -h -k-k-k-k-k.-k.ic-k 
• • • • • • • • • • • • 
H. sap. 250 STMVVAGIFLLIRFHPLAENSPLIQTLTLCLGAITTLFAAVCALTQNDIK 299 
M. mus. 250 STMVVAGIFLLVRFHPLTTNNNFILTTMLCLGALTTLFTAICALTQNDIK 299 
C. ele. 204 STLVTAGLILLMNFNNLVMQK-DFISFVL11GLFTMFFSSLASLVEEDLK 252 
D. mel. 218 STLVTAGVYLLIRFNIILSTS-WLGQLMLLLSGLTMFMAGLGANFEFDLK 266 
A. fra. 205 STLVTAGIYLMIRLS-PSFEE-SGCFLLVVMGALTSFFSGLAAFGENDLK 252 
女• it:** • • • • -k • * • • • • 女 • 女 
• • • • • • • • « • • • • • 
H. sap. 300 KIVAFSTSSQLGLMMVTIGINQPHLAFLHICTHAFFKAMLFMCSGSIIHN 349 
M. mus. 300 KIIAFSTSSQLGLMMVTLGMNQPHLAFLHICTHAFFKAMLFMCSGSIIHS 34 9 
C. ele. 253 KWALSTLSQMGFSMVTLGLGLSFISFIHLVSHALFKSCLFMQVGYIIHC 302 
D. mel. 267 KIIALSTLSQLGLMMSILSMGFLKLAMFHLLTHALFKALLFMCAGAIIHN 316 
A. fra. 253 RVIALSTLSQLGVMMFSLGLGLTLFCYFHLFAHALFKALLFMCSGWIHS 302 
* * • * * • • . ‘ * • *•*••*• * 
• • • • • • • • • • • • * 詹 
H. sap. 350 LNNEQDIRKMGGLLK—TMPLTSTSLTIGSLALAGMPFLTGFYSKDHIIE 397 
M. mus. 350 LADEQDIRKMGNITK—IMPFTSSCLVIGSLALTGMPFLTGFYSKDLIIE 397 
C. ele. 303 SFGQQDGRNYSNNGN—LPNFIQLQMLVTLFCLCGLIFSSGAVSKDFILE 350 
D. mel. 317 MNNSQDIRLMGGLSIGIHMPLTSACFNVSNLALCGMPFLAGFYSKDMILE 366 
A. fra. 303 -LGVQDNRRMGGVSS—MLPYTSYIILVCSLSLMGFPYLSGFFSKDLIIE 34 9 
• * * * . . • : : 
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H. sap. 398 TANMSYTNAWALSITLIATSLTSAYSTRMILLTLTGQPRFPTLTNINENN 447 
M. mus. 398 AINTCNTNAWALLITLIATSMTAMYSMRIIYFVTMTKPRFPPLISINEND 447 
C. ele. 351 LFFSNNYMMFFSLMFFVSVFLTFGYSFRLWKSFFLSFN—KVMNHYSSTV 398 
D. mel. 367 IVSISNVNMFSFFLYYFSTGLTVSYSFRLVYYSMTGDLNCGSLNMLNDES 416 
A. fra. 350 SSES-LCMLFPSVLMLVSCLLTSTYSSRIAMVCLCSYN—YNLSCQYSDE 396 
• • • • "At "A" "AT • • 
H. sap. 448 -PTLLNPIKRLAAGSLFAGFLITNNISPASPFQTTIPLYLKLTALAVTFL 496 
M. mus. 448 -PDLMNPIKRLAFGSIFAGFVISYNIPPTSIPVLTMPWFLKTTALIISVL 496 
C. ele. 399 FMNFLSLVLVIFS ISFLWWMNFN LLNIPSLFLYVD-- 433 
D. mel. 417 WIMLRGMMGLLIMSIIGGSMLNWLIFPFPYMICLPIYMKLLTLFVCIVGG 4 66 
A. fra. 397 EGEYLTPLFVLYWGAVMGGYIFLLMFSG——GDVSIILGPLKSFLLLS— 441 
H. sap. 4 97 GLLTALDLNYLTNKLKMKSPLCTFYFSNMLGFYPSITHRTIPYLGLLTSQ 546 
M. mus. 4 97 GFLIALELNNLTMKLSMNKANPYSSFSTLLGFFPSIIHRITPMKSLNLSL 546 
C. ele. 434 FFGPLVFLFMMIFLSFLILKMLFKELMYKFLVDYL-AKNSIYKMKN 478 
D. mel. 467 LFGYLISLSNLFFLNKSLFMYNLSTFLGSMWFMPYISTYGMIFYPLNYGQ 516 
A. fra. 442 LITVGVILPYFVKSFSLSLSHYVSSMMFLPFITGR-TSFMPLLMGE 486 
• • « « • 
• • • • • 
H. sap. 547 NLPLLLLDLTWLEKLLPKTISQHQISTSIITSTQKGMIKLYFLSFFFPLI 596 
M. mus. 547 KTSLTLLDLIWLEKTIPKSTSTLHTNMTTLTTNQKGLIKLYFMSFLINII 596 
C. ele. 479 LKFMDLFLNNINSKG-YTLFLSSGMF-KNYYLKSLNFNSVWLIFIFFMI 526 
D. mel. 517 LVVKSFDQGWSEYFGGQHLYQKLSMYSKTLFLMHNNSLKIYLLLFVFWIL 566 
A. fra. 487 LLYHEGDCGWVEEAG-PSLIHHNSLR-GSSLFSFLTSSPYKVLILSSLLF 534 
• • • • 
H. sap. 597 LTLLLIT 603 
M. mus. 597 LIIILYSINLE 607 
C. ele. 527 C 527 
D. mel. 567 ILLILLFL——574 
A. fra. 535 TLFMYFYS——542 
Figure 8.1 
Alignment of amino acid sequences of ND5 protein of human mitochondrial DNA 
shows areas of homology and evolutionary conservation in different species. 
Comparison on the variant residues of ProlSLeu, Gly318Ser, and Gly344Gln of ND5 
gene identified in Homo sapiens (H. sap., GenBank accession number:P03915) with 
homologs from Mus musculus (M.mus.’ ND5_10418), Caenorhabditis elegans (C ele., 
CAA38162.1/S26037), Drosophila melanogaster {D. mel., NP_008284) and Artemia 
franciscana (A. fra.’ CAA48813.1). Sequences were aligned by ClustalW 1.7 at 
European Molecular Biology Laboratory (EMBL) (http://www2.ebi.ac.uk/clustalwA. 
Gaps are indicated by hyphens Residue numbering is shown. The bottom row of 
each alignment shows the consensus status of the sequences. The asterisks ‘*, denote 
identical or conserved residues in all sequences in the alignment; the colon ‘：，sign 
indicates conserved substitutions, and the full-stop sign ‘.’ indicates semi-conserved 
substitutions. 
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8.3.3 Four Somatic Mutation Sites Are Detected in More than One 
Cancer Type 
By comparing the results of this study with the mutation spectrum of mutations 
reported on the entire mtDNA genome in Table 4.2, four sites had been already 
detected in other cancers. The first one was a base substitution at 12519 bp in ND5 
gene. The C residue was changed to T in case dl5. This mutation was also found in 
the study of bladder cancer by Fliss et al (Fliss et al, 2000). 
The other three sites were present in the D-loop region. One was a point mutation at 
nucleotide 60. The C residue was changed to T in case dl5 of this study, but it was 
changed to G in a colon cancer study (Hibi et al., 2001b). The other two were 
nucleotide repeat sequences studied in this experiment: a poly-C tract at 303-315 bp 
and a CA repeat at 514 bp. Evaluation of these four sites as putative markers in 
mtDNA for cancers diagnosis will be given in Section 8.7. 
8.3.4 Presence of Homoplasmic and Heteroplasmic Mutations 
Although mtDNA has a large copy number, it is surprising that two-third of the 
mutations found in our study were homoplasmic mutations, where nearly all mtDNA 
molecules had the mutated sequence. The remaining four heteroplasmic mutations 
contained at least 70% of mutated sequences (shown in Figure 7.2). These findings 
can be explained by the two homoplasmic mutation theories mentioned in Section 
4.3. In brief, a mutation arise in a mtDNA molecule may have a replicative 
advantage over the other mtDNA molecules or mitochondria molecules. The 
mutation may arise as a selected clone (Fliss et aL, 2000). Moreover, this replicative 
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advantage may arise randomly as suggested by another group of researchers (Coller 
8.3.5 Absence of Large-scale Deletions in Tumor Tissues 
Section 4.5 describes large-scale deletions of mtDNA (mostly a few thousand base 
pairs) in tumor samples from previous studies (Savre-Train et al, 1992; Bianchi et 
al., 1995; Fukushima et al, 1995; Penta et al., 2001). However, no deletion with 
more than 100-bp was recorded in this study using PCR to amplify fragments from 
871 to 2608 bp. No large deletion was found in another HCC study (Nishikawa et al, 
2001) and recent studies on different types of cancers (Section 4.6). This finding can 
be explained by the fact that those hepatocytes and HCC cells having large deletions 
in their mtDNA might have been eliminated at the level of mitochondrial 
proliferation or tumor cell proliferation, and cells without such deletions may 
continue to proliferate (Kirches et al., 2001; Nishikawa et al, 2001). 
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8.4 Mutation Hotspots Region: Hypervariable Displacement-
loop 
A large proportion of the somatic mutations and polymorphisms in this study were 
found in the D-loop region (42%). Table 8.2 shows that the proportions of somatic 
mutations found in the D-loop region was 14% to 89% in 11 of the 14 studies, and no 
mutation site was found in three studies: two in colon cancer (Habano et al, 1998; 
Polyak et al., 1998) and one in pancreatic xenograft (Jones et al., 2001). The 
proportion of the mutation in D-loop was much higher than its size in the genome 
(6.7%). 
On the other hand, by comparing the number of mutations and size of the respective 
coding or non-coding regions, five somatic mutations were found in the 1,122 bp D-
loop region, and the other seven mutations were found in the coding region, the 
frequency of a somatic mutation found in the D-loop was about ten times higher than 
that in the coding region. 
D-loop region is highly polymorphic and it contains two hypervariable regions: HVl 
and HV2, that are believed to be mutational hotspots. The dominance of transitions 
suggest a common mechanism generating germ-line mtDNA polymorphisms and 
somatic mutations (Stoneking, 2000). Stoneking et al. observed that the average 
evolutionary rates were high in both germ-line and somatic mutations and 
distributions of them in D-loop region were similar (Stoneking, 2000). Therefore, 
both germ-line and somatic mtDNA mutations occurred preferentially at the two 
hypervariable sites, which supports the view that these hypervariable sites are indeed 
mutational hotspots. 
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The D-loop region contains the origin of replication for H-strand synthesis as well as 
mitochondrial transcription promoters of both strands. It is suggested that mutations 
in the D-loop regulatory region may alter the rate of DNA replication by modifying 
the binding affinity of important trans-acting factors (Fliss et al., 2000). The 
existence of hypervariable sites with large number of mutations concludes that D-






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.5 D310 Mononucleotide Repeats 
8.5.1 Description of D310 Mononucleotide Repeats 
丁his region contains repeating C-residues (called poly-cytosine, poly-C or 
homopolymer C-tract) between nucleotide positions 303 and 315 in the D-loop 
region. The sequence is C 7 T C 5 , where the T nucleotide is present at 310 bp. For 
easier designation, this region is referred as D310, a term coined previously by other 
investigators (Marchington et al, 1997). D310 is part of the sequence in the 
conserved sequence block II (299-315 bp) located within the regulatory D-loop 
region. It involves the formation of a persistent RNA-DNA hybrid, leading to the 
initiation of replication of mtDNA heavy-strand (Parrella et al., 2001). 
The first report introducing mutations at D310 was published by Habano et al. in 
colon cancer (Habano et al., 1998). Microsatellite DNA alterations in non-coding D-
loop region were found in 20 of 45 (44%) of colorectal cancer specimens, three of 
which also showed frameshift mutations in Complex I. Later on, other groups found 
sequence variations at D310. The summarized result of studies in D310 is shown in 
Table 8.3. 
8.5.2 Possible Causes of Varied Sequences at D310 
The first possible cause of deletions or insertions at D310 is low fidelity of 
polymerase y. During replication, Pol y has a low frameshift fidelity and proofread 
efficiency in copying mononucleotide sequences longer than four nucleotides. This 
can be found in D310 as its first stretch has seven cytosine residues. The error rate 
would increase with increasing homopolymeric run length (Longley et al., 2001). 
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The poor fidelity in Pol y to the effect of replication in D-loop region requires more 
investigation. 
The next possible cause is the absence of mismatch repair system, which promotes 
slippage of nucleotide repeat sequences at D310 (mentioned in Section 4.2.3). As 
mitochondria have a large number of mtDNA, slippage may occur at some 
mitochondrial genomes, forming new populations of mtDNA. These mutations may 
then have a replicative advantage through clonal selection theory discussed in 
Section 4.3.1 and exist as homoplasmic or heteroplasmic mutations with a high 
percentage of mutated sequence. 
The third possible mechanism is due to increased concentration of ROS and 
enhanced oxidative stress to damage mtDNA which cannot be reduced by defence 
mechanisms. 
These three mechanisms mentioned may cooperate to strengthen the presence of 
varied sequences (Kirches et al., 2001). 
8.5.3 Appearance of Nucleotide Repeats at D310 in Tumors 
From the results, it could be concluded that there were three main variation patterns 
at D310. The first one is identified as normal polymorphisms. Since most of the 
mutations or polymorphisms found in each HCC sample were 1 or 2 bp insertions or 
deletions, which is in the normal polymorphic range of D310 (6-9 Cs in the first 
stretch ofD310). 
-107 -
The second type is called rare polymorphisms. They represent as unusual variants 
with 3- to 4-bp insertion or deletion (5-C，10-C and 11-C in the first stretch of D310). 
In this study, a mixture of 8-C to 10-C was presented in the non-tumor tissue of 
patient d05. In other cancer types, a 3-bp insertion (10-C) were reported in three lung 
cancer cases, eight head and neck cancer cases (Sanchez-Cespedes et al, 2001) and 
one esophageal cancer case (Hibi et al., 2001a). 
The third type is a larger, obvious deletion of more than 5-bp. As mentioned in 
Section 7.4 and Figure 7.3，a 9-bp deletion was found from 314 to 322 bp in patient 
d35 and a 5- or 6-bp deletion including the thymine at 310 bp was found in patient 
d05. The former also deleted the replication primer. In another HCC study (Nomoto 
et al., 2002), a 53-bp and 10-bp deletion was observed in two different primary HCC 
nodules in the same patient. Two other patients had a 5-bp and a 10-bp deletion 
respectively. Obvious deletions of more than 5-bp also occurred in breast (Parrella et 
al, 2001)，colorectal (Habano et al., 1998)，gastric (Burgart et al., 1995) and head 
and neck cancers (Sanchez-Cespedes et al., 2001). The number of obvious deletions 
found in each study is given in Table 8.3. 
8.5.4 Possible Outcomes of D310 Aberrations in mtDNA Replication 
and Transcription 
The D310 repeat site is located at one of the initiation sites for replicating circular 
mitochondrial genome, CSBII (Clayton, 1982). Together with CSBI and CSBIII 
regions，CSBII contributes to the formation of a persistent RNA-DNA hybrid, also 
termed the R-loop, leading to the initiation of mtDNA replication (Xu et al., 1995; 
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Lee et al., 1998). Kang et al reported that the RNA-DNAhybrid was more stable at 
CSB II than at the other CSBs in vivo (Kang et al., 1997). 
The location of D310 at CSBII may give the clue that any deletions or insertions in 
poly-cytosine tract at D310 may alter the CSBII sequence during replication and 
transcription of mitochondrial genome. However, as the first type of mutation in 
tumor (normal polymorphisms in Section 8.5.3) can be found in normal individuals, 
it is suggested that they are unlikely to create functional impairment in mitochondria 
(Sanchez-Cespedes et al” 2001). For the second type (rare polymorphisms), as they 
rarely occur in normal tissue, these mutations may originate during tumor 
progression. 
The third type (large, obvious alteration) in D310 region may play an important role 
in regulating mtDNA replication. From the results, these mutations were originated 
during tumor development (somatic mutations). These changes could lead to 
functional impairment of mitochondria and somehow promote a growth advantage 
for the tumor cell. This finding will serve as an impetus for further research on the 
mechanisms of late replication and processing of mtDNA in cancer (Sanchez-
Cespedes et al., 2001; Tan et al., 2002). Until now, no studies had been done to 
determine whether sequence variants of the D310 region would lead to alterations in 
mtDNA replication. The biological reason for these alterations is still unclear. 
8.5.5 Comparison of D310 Alterations in HCC with Other Cancers 
Twenty-six percent of 50 HCC cases had somatic mutations at D310. From Table 
8.3, it is known that the percentage of cases with somatic mutations varied greatly 
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within the same type of tumor in different studies (for example, from 0% to 44% in 
colorectal cancer and from 0% to 63% in gastric tumor). Sampling bias, geographical 
differences or different technical and interpretive criteria used in each study may 
cause these variations. 
Habano et al. suggested that there is a positive correlation between nuclear genome 
instability and that of mitochondrial genome. Those tumor cases having deletions or 
insertions at D310 tended to show mitochondrial coding mutations in NDl or ND5 
genes, suggesting that these two genes may be one of the target genes for 
mononucleotide repeat in mtDNA in colorectal carcinomas (Habano et al., 1998). 
From our sequencing result involving ten HCC patients for the entire genome 
analysis, a case having a somatic mutation at D310 (patient d05) also had a mutation 
site at ND5 gene (please refer to Figure 7.2 B & I). Since this was observed in a 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































8.6 Other Nucleotide Repeat Sequences 
8.6.1 The CA Dinucleotide Repeats 
The CA dinucleotide repeats contain five CAs presents at the D-loop region 
encompassing nucleotide position from 514 to 525. This repeat sequence does not 
represent any functional region in D-loop. 
From our result, only one somatic mutation was found in 50 HCC cases, suggesting 
that variation of CA repeats at 514 to 525 bp may be infrequent in HCC. There are 
also fewer studies on this dinucleotide CA repeats and results are shown in Table 8.3. 
Excluding the study by Richard et al., they found that 43% of breast cancer had this 
microsatellite instability site (Richard et al., 2000), a low percentage of cases showed 
varied sequences in other studies (from 0% to 8%). 
8.6.2 Other Nucleotide Repeat Sequences Showing Genome Instability 
There are other mono-, di- or trinucleotide repeat sequences in the coding genes of 
mitochondrial genome. They were studied specifically or by analyzing the whole 
genome (Habano et al., 1998; Habano et aL, 2000; Richard et al., 2000). Habano et 
al. and Richard et al. suggested the presence of microsatellite instability (MSI) in 
mitochondrial DNA (mtDNA). MSI is the change of any length in repetitive 
sequences due to insertion or deletion in tumor tissue as compared to normal. 
The other nucleotide repeat sequences which present in the coding genes may cause 
frameshift mutations and may produce truncated proteins. The truncated proteins are 
mostly non-fiinctional. If it is a homoplasmic mutation, the non-functional protein 
will obviously inhibit the energy production process in the cell. 
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From the distribution of somatic mutation sites on Table 4.2, varied sequence was 
found in one CA dinucleotide repeat (514-525) and six mononucleotide repeat 
sequences (66-71, 303-315 (D310), 3566-3571, 12385-12390, 12418-12425 and 
16184-16193). In our study, sequence variations were frequent at D310, 2% in CA 
repeat sequence, and absent in other sites. Parrella et al also suggested mutations 
were detected mainly in the D310 repeat but not in other mitochondrial microsatellite 
sites (Parrella et al., 2001). Therefore, the hypothesis on the presence of 
mitochondrial MSI in cancer may not be applicable in HCC. 
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8.7 Evaluation of Somatic mtDNA Mutations as a Cancer 
Diagnostic Marker 
Several reasons can explain why somatic mtDNA mutations may be used as a 
diagnostic marker to monitor tumor patients: (1) from sequence analysis in 
lymphocytes, it was known that somatic mutations are tumor specific; (2) most 
mtDNA mutations are homoplasmic; (3) mtDNA has a high copy number which may 
be more easily detected than nuclear DNA; and (4) high frequency of mutations have 
been found, with a large proportion of mutations at certain regions (like D-loop and 
D310). 
8.7.1 Coding Region 
The somatic mutations in coding genes may be suitable markers in HCC. From the 
results, the amino acid sequence in three of the four somatic mutation sites is 
conserved in most organisms. If the amino acid sequence is changed, it may cause 
structural and fiinctional changes in human mitochondrial genes, disrupt respiratory 
components and lead to tumor progression. However, the exact nucleotide position(s) 
of the marker may be difficult to be determined as only about 20 sites were found in 
more than one tumor type (Table 4.2). 
8.7.2 D-loop Region 
Mutations in the whole D-loop region may be a potential marker because of the high 
mutation rate in this hypervariable region. This region may be difficult as a marker as 
the evolution rate and distribution of mutations in germ-line and somatic mutations 
in D-loop are similar (Stoneking, 2000). The somatic mutations often existed as 
polymorphisms in normal population. Moreover, as the function of D-loop region has 
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not been fully understood, the effects in some of these mutations to mitochondrial 
function are unknown. Therefore, it may be difficult to determine the presence of 
mutations or differentiate whether these mutations would lead to tumorigenesis. 
8.7.3 D310 Nucleotide Repeats 
D310 abnormalities may be a suitable clonal marker in HCC because of (1) high 
mutation frequency in HCC and many types of tumors, (2) the location of D310 at 
CSBII, and (3) its possible effects in mtDNA replication if mutation occurred. 
Large proportion of variants at D310 is normal polymorphisms (1- or 2-bp 
insertion/deletion). As this is also present in normal tissues, this may create difficulty 
in determining D310 as a suitable marker in HCC. Nevertheless, some rare 
polymorphisms (3- to 4-bp deletion or insertion) and obvious deletions (more than 5-
bp deletion, Section 8.5) found in this study may promote mtDNA replication effects 
and tumor progression. Therefore, alterations at D310 may be one of the most 
possible marker of mtDNA in tumor. 
In one study of head and neck cancer, the presence of D310 changes in 2 of 14 
hyperplastic or dysplastic lesions from 10 patients, indicating that these 
abnormalities can occur early during tumor progression. We can further confirm the 
mutation results by recruiting samples from the pre-neoplastic or paraplastic lesions 
to determine whether it could serve as an early diagnostic marker and possibly, also 
as a prognostic marker. However, it should be noted that the presence of 
heteroplasmic populations of sequences will make it difficult to analyze the relation 
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between the actual mutation behavior of D310 and patients' clinical information 
(Parrella et a/., 2001). 
To conclude, the rare polymorphisms or obvious deletions at D310 and somatic 
mtDNA mutations with amino acid changes may be putative markers of HCC. The 
other microsatellite instability sites or the D-loop region other than D310 may be 
markers in other tumors. As these have not proven yet, more cases would be implied 
to identify whether these regions would be possible markers for cancer detection. 
8.7.4 Possibility of Detecting Somatic Mutations in Serum 
Serum can be a useful tool in the detection of circulating tumor DNA, as it is a non-
invasive method and mtDNA has a higher copy number than nuclear DNA existing 
in serum. Therefore, somatic mutations in serum by automated sequencing should be 
determined. However, as the tumor DNA is rather dilute with respect to normal DNA 
(about 1:200 to 1:500), automated sequencing reaction applied in this experiment 
was not sensitive enough to detect such a small amount of circulating DNA 
molecules. In other studies, mutations in mtDNA can be detected in serum by 
carrying out more sensitive methods, like oligonucleotide mismatch ligation assay 
(Sidransky, 1997). 
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8.8 Somatic mtDNA Mutations May Be a Prognostic Marker 
in HCC 
8.8.1 Possible Problems in Current Prognostic Factors 
Traditional prognostic markers are mostly clinical and histopathological factors, 
which required skilled clinicians and pathologists to determine the clinical stage of 
the tumors. Monitoring substances like AFP in serum is a non-invasive method to 
determine the prognostic value of the tumor's behavior. However, the excessive 
production and / or leakage of AFP due to cell damage may vary with time and the 
results would become inaccurate. For example, severe destruction of hepatocytes 
may induce AFP elevation during the regeneration of hepatocytes which lead to 
misinterpretion of a developing HCC. Several genetic markers have been suggested 
to be a possible prognostic marker for HCC, including p53 (Sugo et al, 1999) and 
smooth muscle calponin (Sasaki et al, 2002). 
8.8.2 Interpretation of Results 
From the result (Section 7.4.2), it was known that the presence or absence of somatic 
mutations at D310 might be significant to both overall and disease-free survivals of 
HCC patients. The medians of overall and disease-free survivals for patients without 
somatic mutations at D310 were approximately 2.8 and 2.6 times in patients with this 
mutation. This was further proven by the significant results found in Cox regression 
univariate analysis. Therefore, presence of mutations at D310 may be a prognostic 
factor for HCC. 
Moreover, the tumors sizes correlated with the survival of patients. It is logical to 
infer that patients with smaller tumor diameter (< 3.0 cm) appear to have higher early 
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survival rates as they are in an earlier stage of HCC. However, this argument may be 
inaccurate as the survival of patients in this study showed smaller tumor size was 
only better than that of patients with larger size (> 6.0 cm) until after about four years 
after the resection of HCC (Figure 7.5). 
8.8.3 Prognostic Values of Somatic Mutations at D310 
Somatic mutations at D310 may be a suitable prognostic factor as they persist in 
mitochondrial DNA in tumor once the mutation occurs. Detection of mutation in the 
serum is quick and more efficient method. It can also combine with the current 
clinicopathological factors to improve the prognostic values of HCC patients. 
The identification of somatic mutations at D310 may help physicians to estimate the 
survival of patients after surgical resection. Suitable patients may be selected for 
novel therapies and clinical trials, particularly because of the poor outcome with 
standard chemotherapy or radiation therapy. 
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8.9 Hypothesis of Somatic MtDNA Mutations on 
Tumorigenesis and Tumor Progression 
Figure 8.2 shows a schematic diagram of the combined hypotheses of somatic 
mtDNA mutations and reactive oxygen species on tumorigenesis and tumor 
progression mentioned in Sections 8.9.1 and 8.9.2. 
8.9.1 Somatic mtDNA Mutations Decline OXPHOS and May Inactivate 
Apoptotic Pathways 
The four somatic mutations in coding genes with altered amino acid sequences 
(Section 7.1.3) may generate abnormal mitochondrial proteins which are respiratory 
enzymes in OXPHOS. This would lead to a series of outcomes with declined energy 
production due to: (1) leakage of electrons from less efficient mitochondrial electron 
transport chain; (2) decline in proton pumping from various complexes, capacitor 
effect and depolarization of mitochondria; (3) alter the mitochondrial transmembrane 
potential; and (4) lower the ATP production from ATP synthase and release of 
calcium (Ozawa, 1995; Jaattela, 1999). 
On the other hand, somatic mutations in the D-loop, replication origin, transcription 
promoters and transcription factor binding sites may affect the proliferation and 
expression of mitochondrial genome, which may also alter pathways in energy 
production. 
Owing to the defects in respiratory complexes in OXPHOS in tumor cells, the energy 
required would rely mainly on ATP produced in the glycolytic pathway from glucose 
(Cavalli et al.’ 1998). Moreover, this decline in respiratory function in tumor cells 
-119 -
would inhibit its apoptosis signaling pathways, which may lead to tumor initiation, 
tumor progression and metastasis promotion. 
8.9.2 Moderate Reactive Oxygen Species Production May Promote 
Mitosis 
During OXPHOS pathway, about one to five percent of electrons leak from the 
electron transport chain and donate to molecular oxygen forming ROS. If they cannot 
be detoxified by defense mechanisms like MnSOD and glutathione peroxidase, they 
may attack mtDNA and induce somatic mutations (mostly base substitutions) and 
strand breaks (Richter et al., 1995). These somatic mutations would generate 
abnormal respiratory enzymes in OXPHOS. 
Mitochondria are suggested to be a possible mediator of apoptotic tumor cell death 
and high concentration of free radicals (ROS) are toxic and can initiate apoptotic cell 
death (Richter et al, 1995; Wallace, 1999). However, somatic mtDNA mutations, 
which may change sequence or structures in OXPHOS complexes, may only 
enhanced ROS production moderately rather than increased greatly (Kirches et al., 
2001). This moderate increase in ROS concentration may become a mitotic stimulus 
in tumor cells rather than an apoptotic stimulus (Li et al., 1997). Therefore, ROS 
may have the role in tumor initiation, promotion or progression. 
The mutant mtDNA and alterations of mitochondrial respiratory function would 
enhance endogenous ROS production by a positive feedback mechanism, further 
mtDNA mutations would be produced and accumulated, thus amplify pathological 
consequences in tumor (Ozawa, 1995; Kirches et al.’ 2001). 
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On the other hand, strand breaks by ROS would form mtDNA fragments 
(transposable elements), which escape from mitochondria and integrate into nuclear 
DNA (Richter et al., 1995). This integration may inactivate genes for the 
maintenance of normal growth control or activate a proto-oncogene, thus 
transforming cells to cancerous state (Li et al., 1997). 
The pathogenic roles of somatic mtDNA mutations in tumorigenesis are not clear yet. 
More extensive biochemical and molecular studies will be necessary to determine the 
effects of mtDNA mutations on energy metabolism and apoptosis in tumor. 
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Figure 8.2 
Hypotheses of the presence of reactive oxygen species and somatic mtDNA mutations 
that could lead to tumor progression. Detailed explanations are mentioned in Section 
8.9. 
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8.10 Possible Appearance of Somatic Mutations in HCC with 
Chronic HBV Infection 
By comparing the presence and abundance of mutated sequences in HCC, adjacent 
non-tumor liver and lymphocytes (buffy coat) in our study, we may find some clues 
on how mutations arise in HCC with the chronic infection of HBV. It is known that if 
a sequence variant was found in mtDNAs from tumor, non-tumor and lymphocytes, 
this mutated sequence is certainly a polymorphism. If a mutation occurs in both 
tumor and non-tumor tissues but not in the corresponding lymphocytes, this mutation 
may be initiated during chronic HBV-infection and/or during repeated destruction 
and regeneration of liver tissue in the developments of cirrhosis of the liver. 
However, the result indicated that these somatic mutations arose in the mtDNA from 
the tumor tissue only and not in the mtDNA from non-tumor or normal lymphocytes. 
The appearance of somatic mutations in the mtDNA may be a late event in HCC 
development and it may be independent to the infection of HBV. 
8.11 Possibility of HBx Protein Integration to MtDNA 
Mutations 
One of the possible roles for the presence of hepatitis B virus-encoded protein, the 
HBx protein (mentioned in Section 1.2), produced after HBV infection is the 
association with voltage-dependent anion channel (VDAC) proteins. 
Voltage-dependent anion channel (VDAC) are abundant proteins ranging from 30 to 
34 kDa that form pores in the outer membranes of mitochondria. VDACs are 
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presumed to act as pathways for ATP and metabolites across mitochondrial 
membrane (Liu et aL, 1992), which is a part of the permeability transition pore 
complex during apoptosis (Rahmani et ai, 2000). 
Rahmani et al. suggested that one of the isoforms of human VDAC (HVDAC3) and 
HBx are localized in mitochondria. This mitochondrial colocalization does not 
require coexpression of either HBx or HVDAC3. Expression of HBV in cultured 
human hepatoma cells leads to alteration of mitochondrial transmembrane potential, 
A中m. Other studies also found VDACs regulate A中m and cytochrome c release. 
However, it is not sure whether cells coexpressing HBx and HVDAC3 have a 
synergistic effect in decreasing A^m (Rahmani et al.’ 2000). 
The association of HBx with mitochondria and HVDAC3 suggests that HBx has an 
indirect role in influencing mitochondrial functions through the induction of either 
apoptotic or antiapoptotic stimuli. These two signals dictate whether a cell 
proliferates or dies. Inappropriate apoptosis has been implicated in cancer. Therefore, 
the roles of HBx and HVDAC3 in affecting mitochondrial physiology may have 
implications for HBV-induced liver injury and the development of hepatocellular 
carcinoma (Rahmani et al., 2000). More investigation is required to delineate the 
relation of the invasion of hepatitis virus and its effects in mitochondria. 
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8.12 Conclusions 
Somatic mutations in mtDNA caused by endogenous ROS may help us to understand 
more about the cause or outcome in cancer development. Through sequence analysis 
of the entire mitochondrial genome, we found that somatic mtDNA mutations are 
frequent genetic abnormalities in HBV-infected HCC. This high mutation frequency 
is also present in many human cancers. As the 1.1 kb displacement loop region is 
hypervariable and polymorphic, it becomes an mutation hotspot. This is proven by 
other studies on different tumor types. 
A specifically high frequency of mutation was found in one of the mononucleotide 
repeat sequence at CSBII: D310. Although most of the somatic mutations were only 
1 or 2 bp insertions or deletions, the remaining mutations may contain obvious 
deletions with more than 5-bp, which may affect transcription and replication of 
mtDNA. By survival analysis, it was found that the somatic mutation at D310 was a 
significant prognostic marker of HCC. So, it is suggested that the presence of 
somatic mutations at D310 would be a possible diagnostic marker for patients with 
HCC, as well as a possible genetic prognostic factor. 
The moderate concentration of ROS in tumor cells would damage mtDNA to 
produce somatic mutations, followed by generation of abnormal proteins in 
OXPHOS complexes. A series of outcomes may promote antiapoptotic effects 
leading to tumor initiation and progression. The leakage of electrons would generate 
a viscous cycle, such that more ROS to produce more mtDNA mutations. 
-125 -
The study of mitochondrial genome in cancer is now an active field. Future 
investigation will provide valuable information to understand the role of somatic 
mitochondrial DNA mutations in carcinogenesis of HCC and other cancers. The 
development of non-invasive detection and screening methods can help us to 
diagnose somatic mtDNA mutations early. 
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Section 9, Limitations and Further Studies 
9.1 Limitations and Improvements of Study 
9.1.1 Small Sample Size 
The mitochondrial genome has a large size, 16.6 kb, a large number of primers were 
required for analyzing the whole mtDNA genome. Due to limited time, the whole 
genome in 10 pairs of HCC and non-tumor samples were analyzed, compared to 
about 10 to 18 cases were studied in other tumors. More samples included will 
provide more representative results: more mutation sites and possible relations with 
clinical data. 
9.1.2 Sequence Analysis Method 
Using automated sequencing alone may be time-consuming and expensive. This is 
not practical for routine analysis. In order to reduce the number of samples for direct 
sequencing, screening method can be applied before sequencing reaction. Two new 
screening methods include two dimensional gene scanning (TDGS) (van Orsouw et 
a / .�1998; Yeh et al.，2000) and temporal temperature gradient gel electrophoresis 
(TTGE) (Chen et al.，1999; Tan et al., 2002). 
In TDGS, a multiplex PGR is first carried out with 25 pairs of primers. The samples 
are applied to a two-dimensional electrophoresis system: first in a nondenaturing gel 
to separate DNA fragments by size, followed by a denaturing gel electrophoresis in 
terms of melting temperature. In TTGE, PGR is first applied using 32 pairs of 
primers. The samples are applied to a denaturing polyacrylamide gel with constant 
concentration of urea and the system electrophoresizes at a temporal temperature 
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gradient (0.5-3°C/h). Double-stranded DNA will become partially denatured and its 
electrophoretic mobility decreases. Mutant and wild-type molecules are separated at 
different denaturing temperatures. 
In these two methods, a single band shift indicates a homoplasmic DNA alteration, 
and a multiple-banding pattern represents a heteroplasmic mutation. Any DNA 
fragments showing differences in banding between the normal and tumor samples are 
sequenced to identify the exact mutations. 
Other traditional screening method may include restriction fragment length 
polymorphism (RFLP) and single strand conformation polymorphism (SSCP). 
9.1.3 Fidelity of PCR Reactions and Long-range PCR Fragments 
In our study, fragments from 871 to 2608 bp were amplified. It is suggested that 
fidelity of the DNA polymerase used in this experiment, AmpliTaq Gold, may not be 
high enough to amplify large molecular size fragments. Moreover, slippage of poly-
cytosine sequence at D310 may occur during PCR amplification. The number and 
proportions of poly-Cs in D310 may be different to their actual profile. In our study, 
a pair of primers with a smaller molecular size (871bp) was used to amplify the 
sequence for D310 region, and repeated PCR and sequencing reactions were carried 
out when a mutation site was suspected to be a somatic mutation. 
Several nuclear psuedogenes on mitochondrial DNA has been identified (Parfait et 
a/., 1998). They are about a few hundred base pairs long. In our study, fragments 
from 871 to 2608 bp were amplified to prevent this problem. 
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Another suggestion to prevent the above problems is to carry out long-distance PCR. 
A polymerase with higher fidelity can be used to amplify nearly the whole 
mitochondrial genome with one pair of primers. In the study of mitochondrial DNA 
mutation by Habano et al (Habano et al, 1998) and van Orsouw et al. (van Orsouw 
et al” 1998)，16526-bp and 16451-bp fragments were amplified respectively. 
9.2 Further Studies 
Screening of somatic mtDNA mutation sites: Sequencing analysis can be carried 
out in more cases to identify more mutation sites and to search for other mutation 
hotspots apart from the D-loop region. The sequence of nucleotide repeat sites can be 
further studied to find out any specific relation with the incidence or progression of 
HCC. Modern analytical methods like gene-chip technologies will give high-
throughput and sensitive results for screening and detecting mutations of the entire 
mitochondrial genome (Chee et al., 1996). As mtDNA has a high copy number, it 
may provide a distinct advantage over nuclear genome-based methods in cancer 
detection. 
Protein functional studies of mutation sites: In the four mutations which changes 
in amino acid sequences, three of them were identical through different species in 
evolution, mutations at these sites may affect protein function. Experiments can be 
carried out to identify whether the amino acid change would greatly affect the 
secondary and tertiary structures of proteins, which associates with their functions. 
-129 -
Somatic mutations on apoptotic behavior: Functional analysis of mutated mtDNA 
to cell behavior can be done by fusing cells lacking mtDNA with mitochondria 
carrying a cancer-derived variant mutant (Liu et al., 2001). Electric shock can fuse 
the cell and mitochondria. Apoptotic assays can be carried out to monitor the effects 
of somatic mutations on apoptotic behavior. We can monitor whether more 
mutations would be generated by sequence analysis of mtDNA in the cells. 
Somatic mutations on tumor cell proliferation: Tumor cells with and without 
certain somatic mutation site(s) can be injected into different groups of nude mice. 
Growth of the tumors can be calculated to determine the effects of somatic mutations 
to tumor proliferation. 
Early diagnostic values of possible markers: As mentioned in Section 8.7.3, 
samples from earlier diagnostic stages like biopsy can be recruited to determine 
whether it could serve as an early diagnostic marker. 
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